A Phase 3 interventional study of Docetaxel and Nab-paclitaxel in Breast Neoplasms, sponsored by Hoffmann-La Roche. Completed at 299 sites in 39 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.
Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2012, is one of 23 in phase 3, and was the 14th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pertuzumab is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 63 · Phase 3 23 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,436 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 104 interventional studies. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 104 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2012, is one of 61 in phase 3, and was the 95th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
10 of the studies testing pertuzumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07187752Shandong Cancer Hospital and InstituteIdentification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes | 2026-12-31 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies testing pertuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
Drug: Docetaxel · Drug: Nab-paclitaxel · Drug: Paclitaxel · Drug: Pertuzumab · Drug: Trastuzumab
Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
Also known as: RO 43-68451
Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
Also known as: Herceptin
Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. TEAEs of special interest included LVEF decreased, liver enzymes increased, and suspected transmission of infectious agent by the study drug.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal
Time frame: The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Number of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal
Time frame: The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events, Occurring in ≥1% of Participants by System Organ Class and Preferred Term
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs by system organ class (SOC) and preferred term (PT); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. If a participant experienced the same AE at more than one severity grade, only the most severe grade was presented.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Treatment-Emergent Adverse Events of Any Grade That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥10% of Participants by System Organ Class
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the system organ classes are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events That Were Related to Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.2% of Participants by Preferred Term
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Discont. = discontinuation; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Treatment (Pertuzumab, Trastuzumab, or Taxane), Occurring in ≥0.5% of Participants by Preferred Term
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Interrupt. = interruption; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Treatment-Emergent Adverse Events to Monitor of Any Grade, Occurring in ≥5% of Participants by Category
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; AEs may fall within multiple categories.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Grade ≥3 Treatment-Emergent Adverse Events to Monitor, Occurring in ≥0.5% of Participants by Category and Preferred Term
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Treatment-Emergent Adverse Events of Special Interest by Category and Preferred Term
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs of special interest included LVEF decreased, liver enzymes (ALT or AST) increased, and suspected transmission of infectious agent by the study drug. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table. If a participant experienced more than one event in a category, they were counted only once in that category.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by Region of Enrollment: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by Age (≤65 vs. >65 Years): Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by Taxane Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), TEAEs Leading to Death, Grade ≥3 TEAEs, Any-Grade and Grade ≥3 TEAEs Related to Pertuzumab, and TEAEs to Monitor
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by ECOG Performance Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by Visceral Disease at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by Hormone Receptor Status at Baseline: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Subgroup Analysis by Previous Trastuzumab Therapy: Overview of the Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs), Grade ≥3 TEAEs, and Grade ≥3 TEAEs Related to Pertuzumab
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With a Congestive Heart Failure Event
Congestive heart failure was defined as the Standardised MedDRA Query (SMQ) 'Cardiac failure (wide)' from the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1).
Time frame: From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Time to Onset of the First Episode of Congestive Heart Failure
Congestive heart failure was defined as SMQ 'Cardiac failure (wide)' from the MedDRA version 22.1. Time to onset of the first episode of congestive heart failure was analyzed using a Kaplan-Meier approach. Participants who did not experience any congestive heart failure at the time of data-cut were censored at the date of the last attended visit whilst on-treatment (including visits up to and including 28 days after last dose of study treatment). Only treatment emergent congestive heart failure events are included.
Time frame: From Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study
All participants must have had a baseline LVEF ≥50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The change from baseline LVEF values were reported at every 3 cycles over the course of the study and at the final treatment, worst treatment, and maximum decrease values. The final treatment value was defined as the last LVEF value observed before all study treatment discontinuation. The worst treatment value was defined as the lowest LVEF value observed before all study treatment discontinuation. The maximum decrease value was defined as the largest decrease of LVEF value from baseline, or minimum increase if a participant's post-baseline LVEF measures were all larger than the baseline value.
Time frame: Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants by Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Categories Over the Course of the Study
All participants must have had a baseline LVEF greater than or equal to (≥)50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The number of participants are reported according to four change from baseline in LVEF value categories over the course of the study: 1) an increase or decrease from baseline LVEF less than (\<)10% points or no change in LVEF; 2) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥10% points to \<15% points; 3) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥15% points; or 4) an absolute LVEF value ≥45% points and a decrease from baseline LVEF ≥10% points. BL = baseline; Decr. = decrease; Incr. = increase
Time frame: Baseline, predose on Day 1 of every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Laboratory Abnormalities in Hematology and Coagulation Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to NCI-CTC v4.0
Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Number of Participants With Laboratory Abnormalities in Biochemistry Parameters: Shift From Baseline to the Worst Post-Baseline Grade According to Normal Range Criteria
Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
Time frame: Predose at each treatment cycle (1 cycle is 3 weeks) from Baseline until 28 days after the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Progression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Age (≤65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
Time frame: From date of enrollment until date of disease progression or death, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Region of Enrollment: Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by ECOG Performance Status at Baseline: Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Taxane Chemotherapy: Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Visceral Disease at Baseline: Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Previous Trastuzumab Therapy: Overall Survival
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
Time frame: From date of enrollment until death due to any cause. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.
Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Percentage of Participants by Best Overall Response as Assessed by the Investigator Using RECIST v1.1
Best overall response (BOR) was defined as the best response recorded from the first dose of study treatment until disease progression/recurrence or death in the absence of disease progression. The hierarchy used to determine BOR: Complete Response (CR)\>Partial Response (PR)\>Stable Disease (SD)\>Progressive Disease (PD)\>Not Evaluable. Note that CR or PR was confirmed ≥4 weeks later. RECIST v1.1 responses are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.; PD = At least 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study, and absolute increase of ≥5 mm.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.
Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Subgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1
The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.
Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression or death. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Clinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.1
The clinical benefit rate was defined as the percentage of participants whose best confirmed response (≥4 weeks later) was a complete response (CR) or partial response (PR), or stable disease (SD) that lasted at least 6 months, as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Clinical benefit responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least 20% increase in sum of diameters of target lesions and absolute increase of ≥5 mm), taking as reference the smallest sum diameters while on study.
Time frame: Assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter, until disease progression. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Duration of Response as Assessed by the Investigator Using RECIST v1.1
Duration of response (DOR) was defined as the time from when a confirmed best overall response of complete response (CR) or partial response (PR) was first documented to first documented disease progression or death from any cause (whichever occurred first). DOR was analyzed using a Kaplan-Meier approach. Participants who had not progressed or died after having had a confirmed response were censored at the date of their last tumor measurement. Response was assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter until event occurrence or end of study. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of first confirmed response (CR or PR) to first documented disease progression or death from any cause, whichever occurred first. The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Time to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.1
Time to response (TTR) was defined as the time from the first study treatment administration to the date of first confirmed response (CR or PR). TTR was analyzed using a Kaplan-Meier approach. Participants who did not have CR or PR were censored at the date of their last evaluable tumor assessment. Participants for whom no post-baseline tumor assessments were available were censored at Day 1. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of first study treatment until date of first confirmed response (CR or PR). The median (full range) duration of follow-up was 68.73 (0.03-87.29) months.
Change From Baseline in Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B) Questionnaire Total Score Over the Course of the Study
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. Participants were given a series of statements in each subscale and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B total score, ranging from 0 to 148, was the sum of the scores for each subscale, provided that at least 80% of the items had been answered; a higher score indicated a better quality of life. If any of the 5 subscale scores were missing, the total score was also set to missing. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Change From Baseline in FACT-B Questionnaire Physical Well-Being Subscale Score Over the Course of the Study
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the physical well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B physical well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Change From Baseline in FACT-B Questionnaire Social Well-Being Subscale Score Over the Course of the Study
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the social well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B social well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Change From Baseline in FACT-B Questionnaire Emotional Well-Being Subscale Score Over the Course of the Study
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the emotional well-being subscale, participants were given a series of 6 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B emotional well-being subscale score, ranging from 0 to 24, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Change From Baseline in FACT-B Questionnaire Functional Well-Being Subscale Score Over the Course of the Study
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the functional well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B functional well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
Change From Baseline in FACT-B Questionnaire Breast Cancer Subscale Score Over the Course of the Study
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the breast cancer subscale, participants were given a series of 10 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B breast cancer subscale score, ranging from 0 to 40, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
Time frame: Baseline, every 3 cycles (1 cycle is 3 weeks) during treatment period, and 28 days post-treatment safety follow-up. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.
| Milestone | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Started | 1436 |
| Received at least one dose of study drug | 1436 |
| Completed | 445 |
| Not completed | 991 |
| Withdrew: Death | 648 |
| Withdrew: Withdrawal by subject | 204 |
| Withdrew: Lost to follow-up | 81 |
| Withdrew: Physician decision | 20 |
| Withdrew: Patient decision | 14 |
| Withdrew: Progressive disease | 8 |
| Withdrew: Site closed before completing form | 6 |
| Withdrew: Enrolled into another trial | 3 |
| Withdrew: Participated in another trial | 3 |
| Withdrew: Termination by sponsor | 2 |
| Withdrew: Patient deterioration | 1 |
| Withdrew: Sponsor decision | 1 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. TEAEs of special interest included LVEF decreased, liver enzymes increased, and suspected transmission of infectious agent by the study drug.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any TEAE - Any Grade | 1419 |
| Any TEAE - Grade 3 or Higher (≥3) | 879 |
| Any Serious TEAE | 535 |
| Any TEAE Leading to Death | 31 |
| Any TEAE Related to Pertuzumab - Any Grade | 1037 |
| Any TEAE Related to Trastuzumab - Any Grade | 946 |
| Any TEAE Related to Taxane - Any Grade | 1342 |
| Any TEAE Related to Pertuzumab - Grade ≥3 | 286 |
| Any TEAE Related to Trastuzumab - Grade ≥3 | 245 |
| Any TEAE Related to Taxane - Grade ≥3 | 514 |
| Any TEAE Leading to Interruption of Pertuzumab | 334 |
| Any TEAE Leading to Interruption of Trastuzumab | 386 |
| Any TEAE Leading to Interruption of Taxane | 354 |
| Any TEAE Leading to Discontinuation of Pertuzumab | 140 |
| Any TEAE Leading to Discontinuation of Trastuzumab | 133 |
| Any TEAE Leading to Discontinuation of Taxane | 286 |
| Any TEAE to Monitor - Any Grade | 1320 |
| Any TEAE to Monitor - Grade ≥3 | 535 |
| Any TEAE of Special Interest | 91 |
| Any TEAE Within 28 Days of Treatmt Discontinuation | 975 |
All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Total Number of Deaths | 658 |
| Number of Deaths by Cause: Progressive Disease | 581 |
| Number of Deaths by Cause: Other | 42 |
| Number of Deaths by Cause: Adverse Event (Total) | 35 |
| Infections and Infestations (SOC) | 11 |
| Peritonitis (PT) | 1 |
| Pneumonia (PT) | 5 |
| Respiratory Tract Infection (PT) | 1 |
| Sepsis (PT) | 3 |
| Septic Shock (PT) | 1 |
| Cardiac Disorders (SOC) | 7 |
| Cardiac Arrest (PT) | 2 |
| Cardiac Failure (PT) | 1 |
| Cardiac Failure Congestive (PT) | 1 |
| Cardio-respiratory Arrest (PT) | 1 |
| Myocardial Infarction (PT) | 1 |
| Right Ventricular Failure (PT) | 1 |
| General Disorders & Admin. Site Conditions (SOC) | 6 |
| Death (PT) | 6 |
| Blood and Lymphatic System Disorders (SOC) | 3 |
| Febrile Neutropenia (PT) | 1 |
| Neutropenia (PT) | 1 |
| Thrombocytopenia (PT) | 1 |
| Respiratory, Thoracic & Mediast. Disorders (SOC) | 3 |
| Acute Respiratory Distress Syndrome (PT) | 1 |
| Aspiration (PT) | 1 |
| Pneumonitis (PT) | 1 |
| Gastrointestinal Disorders (SOC) | 2 |
| Pancreatitis (PT) | 1 |
| Pancreatitis Chronic (PT) | 1 |
| Nervous System Disorders (SOC) | 2 |
| Hepatic Encephalopathy (PT) | 1 |
| Ischemic Stroke (PT) | 1 |
| Metabolism and Nutrition Disorders (SOC) | 1 |
| Hypoglycaemia (PT) | 1 |
| Hepatobiliary Disorders (SOC) | 1 |
| Hepatic Failure (PT) | 1 |
| Psychiatric Disorders (SOC) | 1 |
| Delirium (PT) | 1 |
All adverse events leading to death, regardless of whether they were classified as treatment emergent, are listed by system organ class (SOC) and preferred term (PT) according to the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. Admin. = administration; Mediast. = mediastinal
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Total Number of Deaths | 38 |
| Number of Deaths by Cause: Progressive Disease | 18 |
| Number of Deaths by Cause: Other | 1 |
| Number of Deaths by Cause: Adverse Event (Total) | 19 |
| Infections and Infestations (SOC) | 6 |
| Peritonitis (PT) | 1 |
| Pneumonia (PT) | 2 |
| Respiratory Tract Infection (PT) | 1 |
| Sepsis (PT) | 2 |
| General Disorders & Admin. Site Conditions (SOC) | 4 |
| Death (PT) | 4 |
| Blood and Lymphatic System Disorders (SOC) | 3 |
| Febrile Neutropenia (PT) | 1 |
| Neutropenia (PT) | 1 |
| Thrombocytopenia (PT) | 1 |
| Cardiac Disorders (SOC) | 2 |
| Cardiac Arrest (PT) | 1 |
| Cardio-Respiratory Arrest (PT) | 1 |
| Respiratory, Thoracic & Mediast. Disorders (SOC) | 2 |
| Acute Respiratory Distress Syndrome (PT) | 1 |
| Pneumonitis (PT) | 1 |
| Gastrointestinal Disorders (SOC) | 1 |
| Pancreatitis (PT) | 1 |
| Nervous System Disorders (SOC) | 1 |
| Hepatic Encephalopathy (PT) | 1 |
| Metabolism and Nutrition Disorders (SOC) | 1 |
| Hypoglycaemia (PT) | 1 |
| Hepatobiliary Disorders (SOC) | 1 |
| Hepatic Failure (PT) | 1 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs by system organ class (SOC) and preferred term (PT); PTs that are part of a given SOC are listed in the rows directly below each SOC within the results table. If a participant experienced the same AE at more than one severity grade, only the most severe grade was presented.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any TEAE - Grade (Gr.) 3 | 676 |
| Any TEAE - Gr. 4 | 172 |
| Any TEAE - Gr. 5 | 31 |
| Gastrointestinal Disorders (SOC) - Gr. 3 | 163 |
| Gastrointestinal Disorders (SOC) - Gr. 4 | 4 |
| Gastrointestinal Disorders (SOC) - Gr. 5 | 2 |
| Diarrhoea (PT) - Gr. 3 | 119 |
| Diarrhoea (PT) - Gr. 4 | 1 |
| Diarrhoea (PT) - Gr. 5 | 0 |
| Vomiting (PT) - Gr. 3 | 19 |
| Vomiting (PT) - Gr. 4 | 0 |
| Vomiting (PT) - Gr. 5 | 0 |
| Skin & Subcutaneous Tissue Disorders (SOC) - Gr. 3 | 56 |
| Skin & Subcutaneous Tissue Disorders (SOC) - Gr. 4 | 0 |
| Skin & Subcutaneous Tissue Disorders (SOC) - Gr. 5 | 0 |
| Gen. Disorders & Admin.Site Conditions (SOC)-Gr. 3 | 100 |
| Gen. Disorders & Admin.Site Conditions (SOC)-Gr. 4 | 0 |
| Gen. Disorders & Admin.Site Conditions (SOC)-Gr. 5 | 3 |
| Fatigue (PT) - Gr. 3 | 36 |
| Fatigue (PT) - Gr. 4 | 0 |
| Fatigue (PT) - Gr. 5 | 0 |
| Asthenia (PT) - Gr. 3 | 29 |
| Asthenia (PT) - Gr. 4 | 0 |
| Asthenia (PT) - Gr. 5 | 0 |
| Mucosal Inflammation (PT) - Gr. 3 | 14 |
| Mucosal Inflammation (PT) - Gr. 4 | 0 |
| Mucosal Inflammation (PT) - Gr. 5 | 0 |
| Nervous System Disorders (SOC) - Gr. 3 | 139 |
| Nervous System Disorders (SOC) - Gr. 4 | 0 |
| Nervous System Disorders (SOC) - Gr. 5 | 2 |
| Neuropathy Peripheral (PT) - Gr. 3 | 26 |
| Neuropathy Peripheral (PT) - Gr. 4 | 0 |
| Neuropathy Peripheral (PT) - Gr. 5 | 0 |
| Syncope (PT) - Gr. 3 | 24 |
| Syncope (PT) - Gr. 4 | 0 |
| Syncope (PT) - Gr. 5 | 0 |
| Headache (PT) - Gr. 3 | 17 |
| Headache (PT) - Gr. 4 | 0 |
| Headache (PT) - Gr. 5 | 0 |
| Paraesthesia (PT) - Gr. 3 | 14 |
| Paraesthesia (PT) - Gr. 4 | 0 |
| Paraesthesia (PT) - Gr. 5 | 0 |
| Peripheral Sensory Neuropathy (PT) - Gr. 3 | 14 |
| Peripheral Sensory Neuropathy (PT) - Gr. 4 | 0 |
| Peripheral Sensory Neuropathy (PT) - Gr. 5 | 0 |
| Infections and Infestations (SOC) - Gr. 3 | 148 |
| Infections and Infestations (SOC) - Gr. 4 | 19 |
| Infections and Infestations (SOC) - Gr. 5 | 10 |
| Pneumonia (PT) - Gr. 3 | 22 |
| Pneumonia (PT) - Gr. 4 | 1 |
| Pneumonia (PT) - Gr. 5 | 4 |
| Vascular Device Infection (PT) - Gr. 3 | 14 |
| Vascular Device Infection (PT) - Gr. 4 | 0 |
| Vascular Device Infection (PT) - Gr. 5 | 0 |
| Device Related Infection (PT) - Gr. 3 | 14 |
| Device Related Infection (PT) - Gr. 4 | 0 |
| Device Related Infection (PT) - Gr. 5 | 0 |
| Musculo. & Connective Tissue Disorders (SOC)-Gr. 3 | 75 |
| Musculo. & Connective Tissue Disorders (SOC)-Gr. 4 | 0 |
| Musculo. & Connective Tissue Disorders (SOC)-Gr. 5 | 0 |
| Resp., Thoracic & Mediast. Disorders (SOC) - Gr. 3 | 62 |
| Resp., Thoracic & Mediast. Disorders (SOC) - Gr. 4 | 5 |
| Resp., Thoracic & Mediast. Disorders (SOC) - Gr. 5 | 3 |
| Pulmonary Embolism (PT) - Gr. 3 | 21 |
| Pulmonary Embolism (PT) - Gr. 4 | 2 |
| Pulmonary Embolism (PT) - Gr. 5 | 0 |
| Dyspnoea (PT) - Gr. 3 | 19 |
| Dyspnoea (PT) - Gr. 4 | 1 |
| Dyspnoea (PT) - Gr. 5 | 0 |
| Blood & Lymphatic System Disorders (SOC) - Gr. 3 | 158 |
| Blood & Lymphatic System Disorders (SOC) - Gr. 4 | 104 |
| Blood & Lymphatic System Disorders (SOC) - Gr. 5 | 3 |
| Neutropenia (PT) - Gr. 3 | 77 |
| Neutropenia (PT) - Gr. 4 | 67 |
| Neutropenia (PT) - Gr. 5 | 1 |
| Febrile Neutropenia (PT) - Gr. 3 | 51 |
| Febrile Neutropenia (PT) - Gr. 4 | 38 |
| Febrile Neutropenia (PT) - Gr. 5 | 1 |
| Anaemia (PT) - Gr. 3 | 29 |
| Anaemia (PT) - Gr. 4 | 0 |
| Anaemia (PT) - Gr. 5 | 0 |
| Leukopenia (PT) - Gr. 3 | 15 |
| Leukopenia (PT) - Gr. 4 | 3 |
| Leukopenia (PT) - Gr. 5 | 0 |
| Investigations (SOC) - Gr. 3 | 116 |
| Investigations (SOC) - Gr. 4 | 20 |
| Investigations (SOC) - Gr. 5 | 0 |
| Neutrophil Count Decreased (PT) - Gr. 3 | 25 |
| Neutrophil Count Decreased (PT) - Gr. 4 | 13 |
| Neutrophil Count Decreased (PT) - Gr. 5 | 0 |
| Ejection Fraction Decreased (PT) - Gr. 3 | 22 |
| Ejection Fraction Decreased (PT) - Gr. 4 | 2 |
| Ejection Fraction Decreased (PT) - Gr. 5 | 0 |
| Gamma-Glutamyltransferase Increased (PT) - Gr. 3 | 19 |
| Gamma-Glutamyltransferase Increased (PT) - Gr. 4 | 1 |
| Gamma-Glutamyltransferase Increased (PT) - Gr. 5 | 0 |
| White Blood Cell Count Decreased (PT) - Gr. 3 | 16 |
| White Blood Cell Count Decreased (PT) - Gr. 4 | 2 |
| White Blood Cell Count Decreased (PT) - Gr. 5 | 0 |
| Alanine Aminotransferase Increased (PT) - Gr. 3 | 16 |
| Alanine Aminotransferase Increased (PT) - Gr. 4 | 0 |
| Alanine Aminotransferase Increased (PT) - Gr. 5 | 0 |
| Metabolism and Nutrition Disorders (SOC) - Gr. 3 | 63 |
| Metabolism and Nutrition Disorders (SOC) - Gr. 4 | 8 |
| Metabolism and Nutrition Disorders (SOC) - Gr. 5 | 1 |
| Hypokalaemia (PT) - Gr. 3 | 19 |
| Hypokalaemia (PT) - Gr. 4 | 1 |
| Hypokalaemia (PT) - Gr. 5 | 0 |
| Vascular Disorders (SOC) - Gr. 3 | 62 |
| Vascular Disorders (SOC) - Gr. 4 | 2 |
| Vascular Disorders (SOC) - Gr. 5 | 0 |
| Hypertension (PT) - Gr. 3 | 45 |
| Hypertension (PT) - Gr. 4 | 1 |
| Hypertension (PT) - Gr. 5 | 0 |
| Psychiatric Disorders (SOC) - Gr. 3 | 15 |
| Psychiatric Disorders (SOC) - Gr. 4 | 3 |
| Psychiatric Disorders (SOC) - Gr. 5 | 1 |
| Injury, Poisoning & Proced. Complicat. (SOC)-Gr. 3 | 43 |
| Injury, Poisoning & Proced. Complicat. (SOC)-Gr. 4 | 6 |
| Injury, Poisoning & Proced. Complicat. (SOC)-Gr. 5 | 0 |
| Cardiac Disorders (SOC) - Gr. 3 | 35 |
| Cardiac Disorders (SOC) - Gr. 4 | 5 |
| Cardiac Disorders (SOC) - Gr. 5 | 7 |
| Immune System Disorders (SOC) - Gr. 3 | 17 |
| Immune System Disorders (SOC) - Gr. 4 | 1 |
| Immune System Disorders (SOC) - Gr. 5 | 0 |
| Renal and Urinary Disorders (SOC) - Gr. 3 | 15 |
| Renal and Urinary Disorders (SOC) - Gr. 4 | 3 |
| Renal and Urinary Disorders (SOC) - Gr. 5 | 0 |
| Neoplasms Benign, Malignant & Unspec. (SOC) -Gr. 3 | 13 |
| Neoplasms Benign, Malignant & Unspec. (SOC) -Gr. 4 | 5 |
| Neoplasms Benign, Malignant & Unspec. (SOC) -Gr. 5 | 0 |
| Hepatobiliary Disorders (SOC) - Gr. 3 | 13 |
| Hepatobiliary Disorders (SOC) - Gr. 4 | 0 |
| Hepatobiliary Disorders (SOC) - Gr. 5 | 1 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the system organ classes are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any TEAE Related to Pertuzumab (Rel to Ptz) | 1037 |
| Rel to Ptz: Gastrointestinal Disorders | 629 |
| Rel to Ptz: Skin and Subcutaneous Tissue Disorders | 491 |
| Rel to Ptz: Gen. Disorders & Admin.Site Conditions | 462 |
| Rel to Ptz: Investigations | 252 |
| Rel to Ptz: Nervous System Disorders | 207 |
| Rel to Ptz: Resp., Thoracic & Mediast. Disorders | 188 |
| Rel to Ptz: Musculo. & Connective Tissue Disorders | 184 |
| Rel to Ptz: Blood & Lymphatic System Disorders | 182 |
| Rel to Ptz: Infections and Infestations | 151 |
| Any TEAE Related to Trastuzumab (Rel to Trz) | 946 |
| Rel to Trz: Gastrointestinal Disorders | 435 |
| Rel to Trz: Gen. Disorders & Admin.Site Conditions | 434 |
| Rel to Trz: Skin and Subcutaneous Tissue Disorders | 384 |
| Rel to Trz: Investigations | 262 |
| Rel to Trz: Nervous System Disorders | 184 |
| Rel to Trz: Musculo. & Connective Tissue Disorders | 179 |
| Rel to Trz: Blood & Lymphatic System Disorders | 163 |
| Rel to Trz: Resp., Thoracic & Mediast. Disorders | 153 |
| Any TEAE Related to Taxane (Rel to Tax) | 1342 |
| Rel to Tax: Gastrointestinal Disorders | 984 |
| Rel to Tax: Skin and Subcutaneous Tissue Disorders | 938 |
| Rel to Tax: Gen. Disorders & Admin.Site Conditions | 834 |
| Rel to Tax: Nervous System Disorders | 764 |
| Rel to Tax: Blood & Lymphatic System Disorders | 457 |
| Rel to Tax: Musculo. & Connective Tissue Disorders | 386 |
| Rel to Tax: Infections and Infestations | 293 |
| Rel to Tax: Resp., Thoracic & Mediast. Disorders | 290 |
| Rel to Tax: Metabolism and Nutrition Disorders | 227 |
| Rel to Tax: Investigations | 201 |
| Rel to Tax: Eye Disorders | 174 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any Grade ≥3 TEAE Related to Pertuz. (Rel to Ptz) | 286 |
| Rel to Ptz: Diarrhoea | 59 |
| Rel to Ptz: Neutropenia | 28 |
| Rel to Ptz: Febrile Neutropenia | 28 |
| Rel to Ptz: Ejection Fraction Decreased | 19 |
| Rel to Ptz: Neutrophil Count Decreased | 15 |
| Rel to Ptz: Fatigue | 15 |
| Rel to Ptz: Left Ventricular Dysfunction | 10 |
| Rel to Ptz: Asthenia | 10 |
| Rel to Ptz: White Blood Cell Count Decreased | 10 |
| Rel to Ptz: Cardiac Failure | 9 |
| Any Grade ≥3 TEAE Related to Trastuz. (Rel to Trz) | 245 |
| Rel to Trz: Diarrhoea | 32 |
| Rel to Trz: Neutropenia | 30 |
| Rel to Trz: Ejection Fraction Decreased | 23 |
| Rel to Trz: Febrile Neutropenia | 21 |
| Rel to Trz: Neutrophil Count Decreased | 15 |
| Rel to Trz: Fatigue | 14 |
| Rel to Trz: Left Ventricular Dysfunction | 11 |
| Rel to Trz: White Blood Cell Count Decreased | 10 |
| Rel to Trz: Cardiac Failure | 8 |
| Rel to Trz: Asthenia | 8 |
| Any Grade ≥3 TEAE Related to Taxane (Rel to Tax) | 514 |
| Rel to Tax: Neutropenia | 140 |
| Rel to Tax: Febrile Neutropenia | 86 |
| Rel to Tax: Diarrhoea | 80 |
| Rel to Tax: Neutrophil Count Decreased | 34 |
| Rel to Tax: Fatigue | 26 |
| Rel to Tax: Peripheral Neuropathy | 24 |
| Rel to Tax: Asthenia | 20 |
| Rel to Tax: Leukopenia | 16 |
| Rel to Tax: White Blood Cell Count Decreased | 16 |
| Rel to Tax: Mucosal Inflammation | 14 |
| Rel to Tax: Paraesthesia | 13 |
| Rel to Tax: Peripheral Sensory Neuropathy | 13 |
| Rel to Tax: Onycholysis | 10 |
| Rel to Tax: Neutropenic Sepsis | 10 |
| Rel to Tax: Anaemia | 10 |
| Rel to Tax: Vomiting | 7 |
| Rel to Tax: Neurotoxicity | 7 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Discont. = discontinuation; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any TEAE, Pertuzumab Discontinuation (Ptz Discont) | 140 |
| Ptz Discont: Ejection Fraction Decreased | 37 |
| Ptz Discont: Cardiac Failure | 10 |
| Ptz Discont: Left Ventricular Dysfunction | 7 |
| Ptz Discont: Diarrhoea | 7 |
| Ptz Discont: Dyspnoea | 4 |
| Ptz Discont: Infusion Related Reaction | 4 |
| Ptz Discont: Sepsis | 3 |
| Ptz Discont: Neuropathy Peripheral | 3 |
| Ptz Discont: Hypersensitivity | 3 |
| Ptz Discont: General Physical Health Deterioration | 3 |
| Any TEAE, Trastuzumab Discontinuation(Trz Discont) | 133 |
| Trz Discont: Ejection Fraction Decreased | 37 |
| Trz Discont: Cardiac Failure | 10 |
| Trz Discont: Left Ventricular Dysfunction | 7 |
| Trz Discont: Diarrhoea | 6 |
| Trz Discont: Sepsis | 3 |
| Trz Discont: Dyspnoea | 3 |
| Trz Discont: Neuropathy Peripheral | 3 |
| Trz Discont: Hypersensitivity | 3 |
| Trz Discont: General Physical Health Deterioration | 3 |
| Any TEAE, Taxane Discontinuation (Tax Discont) | 286 |
| Tax Discont: Neuropathy Peripheral | 52 |
| Tax Discont: Peripheral Sensory Neuropathy | 25 |
| Tax Discont: Paraesthesia | 24 |
| Tax Discont: Diarrhoea | 19 |
| Tax Discont: Fatigue | 16 |
| Tax Discont: Asthenia | 13 |
| Tax Discont: Onycholysis | 8 |
| Tax Discont: Nail Toxicity | 7 |
| Tax Discont: Neurotoxicity | 7 |
| Tax Discont: Polyneuropathy | 7 |
| Tax Discont: Oedema Peripheral | 7 |
| Tax Discont: Febrile Neutropenia | 7 |
| Tax Discont: Neutropenia | 7 |
| Tax Discont: Dyspnoea | 6 |
| Tax Discont: Decreased Appetite | 6 |
| Tax Discont: Ejection Fraction Decreased | 5 |
| Tax Discont: General Physical Health Deterioration | 4 |
| Tax Discont: Mucosal Inflammation | 4 |
| Tax Discont: Rash | 4 |
| Tax Discont: Anaemia | 4 |
| Tax Discont: Arthralgia | 4 |
| Tax Discont: Drug Hypersensitivity | 4 |
| Tax Discont: Dysgeusia | 3 |
| Tax Discont: Nail Disorder | 3 |
| Tax Discont: Nail Dystrophy | 3 |
| Tax Discont: Skin Toxicity | 3 |
| Tax Discont: Pneumonia | 3 |
| Tax Discont: Sepsis | 3 |
| Tax Discont: Pleural Effusion | 3 |
| Tax Discont: Pneumonitis | 3 |
| Tax Discont: Cardiac Failure | 3 |
| Tax Discont: Myalgia | 3 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. MedDRA version 22.1 was used to code AEs and the preferred terms are presented in descending order according to the total frequency of occurrence. If a participant experienced more than one event in a category, they were counted only once in that category. Interrupt. = interruption; Ptz = pertuzumab; Tax = taxane; Trz = trastuzumab
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any TEAE, Pertuzumab Interruption (Ptz Interrupt) | 334 |
| Ptz Interrupt: Ejection Fraction Decreased | 51 |
| Ptz Interrupt: Diarrhoea | 21 |
| Ptz Interrupt: Neutropenia | 17 |
| Ptz Interrupt: Pneumonia | 14 |
| Ptz Interrupt: Upper Respiratory Tract Infection | 13 |
| Ptz Interrupt: Pyrexia | 11 |
| Ptz Interrupt: Dyspnoea | 11 |
| Ptz Interrupt: Drug Hypersensitivity | 9 |
| Ptz Interrupt: Influenza | 8 |
| Ptz Interrupt: Asthenia | 8 |
| Ptz Interrupt: Neutrophil Count Decreased | 8 |
| Ptz Interrupt: Nasopharyngitis | 7 |
| Ptz Interrupt: Anaemia | 7 |
| Any TEAE, Trastuzumab Interruption (Trz Interrupt) | 386 |
| Trz Interrupt: Ejection Fraction Decreased | 52 |
| Trz Interrupt: Drug Hypersensitivity | 31 |
| Trz Interrupt: Diarrhoea | 20 |
| Trz Interrupt: Pyrexia | 18 |
| Trz Interrupt: Neutropenia | 17 |
| Trz Interrupt: Dyspnoea | 17 |
| Trz Interrupt: Pneumonia | 14 |
| Trz Interrupt: Chills | 13 |
| Trz Interrupt: Infusion Related Reaction | 13 |
| Trz Interrupt: Upper Respiratory Tract Infection | 12 |
| Trz Interrupt: Neutrophil Count Decreased | 8 |
| Trz Interrupt: Influenza | 7 |
| Trz Interrupt: Asthenia | 7 |
| Trz Interrupt: Vomiting | 7 |
| Trz Interrupt: Anaemia | 7 |
| Trz Interrupt: Nasopharyngitis | 7 |
| Any TEAE, Taxane Interruption (Tax Interrupt) | 354 |
| Tax Interrupt: Neutropenia | 46 |
| Tax Interrupt: Diarrhoea | 30 |
| Tax Interrupt: Leukopenia | 17 |
| Tax Interrupt: Dyspnoea | 15 |
| Tax Interrupt: Pyrexia | 14 |
| Tax Interrupt: Neutrophil Count Decreased | 14 |
| Tax Interrupt: Ejection Fraction Decreased | 13 |
| Tax Interrupt: Neuropathy Peripheral | 13 |
| Tax Interrupt: Nasopharyngitis | 10 |
| Tax Interrupt: Drug Hypersensitivity | 10 |
| Tax Interrupt: Fatigue | 10 |
| Tax Interrupt: Upper Respiratory Tract Infection | 9 |
| Tax Interrupt: Infusion Related Reaction | 9 |
| Tax Interrupt: Asthenia | 9 |
| Tax Interrupt: Erythema | 8 |
| Tax Interrupt: Pneumonia | 7 |
| Tax Interrupt: Flushing | 7 |
| Tax Interrupt: Hypersensitivity | 7 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; AEs may fall within multiple categories.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any TEAE to Monitor | 1320 |
| Infusion-/Administration-Related Reactions | 1096 |
| Rash/Skin Reactions | 668 |
| Mucositis | 618 |
| Cardiac Dysfunction | 478 |
| Neutropenia/Febrile Neutropenia | 439 |
| Anaphylaxis and Hypersensitivity | 124 |
| Diarrhoea Grade ≥3 | 120 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first dose of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, it was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. If a participant had more than one event in a category, they were counted only once in that category. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any Grade ≥3 TEAE to Monitor | 535 |
| Neutropenia/Febrile Neutropenia (Category) | 279 |
| Neutropenia (PT) | 145 |
| Febrile Neutropenia (PT) | 90 |
| Neutrophil Count Decreased (PT) | 38 |
| Leukopenia (PT) | 18 |
| White Blood Cell Count Decreased (PT) | 18 |
| Neutropenic Sepsis (PT) | 10 |
| Infusion-/Admin.-Related Reactions (Category) | 123 |
| Hypertension (PT) | 27 |
| IRR/ARR: Drug Hypersensitivity (PT) | 12 |
| Asthenia (PT) | 11 |
| Fatigue (PT) | 11 |
| Dyspnoea (PT) | 10 |
| Infusion Related Reaction (PT) | 8 |
| Paraesthesia (PT) | 7 |
| Diarrhoea Grade ≥3 (Category) | 120 |
| Diarrhoea (PT) | 120 |
| Cardiac Dysfunction (Category) | 51 |
| Ejection Fraction Decreased (PT) | 24 |
| Left Ventricular Dysfunction (PT) | 11 |
| Cardiac Failure (PT) | 9 |
| Mucositis (Category) | 33 |
| Mucosal Inflammation (PT) | 14 |
| Stomatitis (PT) | 9 |
| Rash/Skin Reactions (Category) | 28 |
| Rash (PT) | 10 |
| Anaphylaxis and Hypersensitivity (Category) | 18 |
| Anaphyl./Hypersens.: Drug Hypersensitivity (PT) | 13 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs of special interest included LVEF decreased, liver enzymes (ALT or AST) increased, and suspected transmission of infectious agent by the study drug. MedDRA version 22.1 was used to code AEs; preferred terms (PT) that are part of a given category are listed in the rows directly below each category within the results table. If a participant experienced more than one event in a category, they were counted only once in that category.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Any TEAE of Special Interest | 91 |
| Decline in LVEF (Category) | 90 |
| Ejection Fraction Decreased (PT) | 75 |
| Left Ventricular Dysfunction (PT) | 8 |
| Cardiac Failure (PT) | 7 |
| Cardiac Failure Congestive (PT) | 1 |
| Elevated ALT or AST (Category) | 1 |
| Hepatic Failure (PT) | 1 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
| Participants | Europe | Asia | North America | South America | Africa | Other (Australia) |
|---|---|---|---|---|---|---|
| Any Serious TEAE | 385 | 74 | 9 | 37 | 16 | 14 |
| Any TEAE - Grade 3 or Higher (≥3) | 632 | 109 | 22 | 63 | 37 | 16 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 187 | 44 | 5 | 27 | 19 | 4 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.
| Participants | Age ≤65 Years | Age >65 Years |
|---|---|---|
| Any Serious TEAE | 415 | 120 |
| Any TEAE Leading to Death | 17 | 14 |
| Any TEAE - Grade 3 or Higher (≥3) | 688 | 191 |
| Any TEAE Related to Pertuzumab - Any Grade | 845 | 192 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 224 | 62 |
| Any TEAE to Monitor - Any Grade | 1081 | 239 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade ≥3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent.
| Participants | Docetaxel | Paclitaxel | Nab-Paclitaxel |
|---|---|---|---|
| Any Serious TEAE | 300 | 210 | 22 |
| Any TEAE Leading to Death | 14 | 16 | 1 |
| Any TEAE - Grade 3 or Higher (≥3) | 491 | 349 | 36 |
| Any TEAE Related to Pertuzumab - Any Grade | 547 | 434 | 52 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 171 | 105 | 9 |
| Any TEAE to Monitor - Any Grade | 709 | 541 | 64 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
| Participants | ECOG Performance Status 0 or 1 | ECOG Performance Status 2 |
|---|---|---|
| Any Serious TEAE | 502 | 33 |
| Any TEAE - Grade 3 or Higher (≥3) | 837 | 41 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 273 | 13 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
| Participants | Visceral Disease | Non-Visceral Disease |
|---|---|---|
| Any Serious TEAE | 353 | 182 |
| Any TEAE - Grade 3 or Higher (≥3) | 610 | 269 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 197 | 89 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
| Participants | Prior (Neo)Adjuvant Chemotherapy | No Prior (Neo)Adjuvant Chemotherapy |
|---|---|---|
| Any Serious TEAE | 283 | 252 |
| Any TEAE - Grade 3 or Higher (≥3) | 493 | 386 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 169 | 117 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
| Participants | Hormone Receptor Positive | Hormone Receptor Negative | Hormone Receptor Status Unknown |
|---|---|---|---|
| Any Serious TEAE | 353 | 179 | 3 |
| Any TEAE - Grade 3 or Higher (≥3) | 573 | 303 | 3 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 181 | 103 | 2 |
Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
| Participants | Previous Trastuzumab Therapy | No Previous Trastuzumab Therapy |
|---|---|---|
| Any Serious TEAE | 135 | 400 |
| Any TEAE - Grade 3 or Higher (≥3) | 238 | 641 |
| Any Grade ≥3 TEAE Related to Pertuzumab | 77 | 209 |
Congestive heart failure was defined as the Standardised MedDRA Query (SMQ) 'Cardiac failure (wide)' from the Medical Dictionary for Regulatory Activities, version 22.1 (MedDRA version 22.1).
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Number of Participants With a Congestive Heart Failure Event | 478 |
Congestive heart failure was defined as SMQ 'Cardiac failure (wide)' from the MedDRA version 22.1. Time to onset of the first episode of congestive heart failure was analyzed using a Kaplan-Meier approach. Participants who did not experience any congestive heart failure at the time of data-cut were censored at the date of the last attended visit whilst on-treatment (including visits up to and including 28 days after last dose of study treatment). Only treatment emergent congestive heart failure events are included.
| Months | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Time to Onset of the First Episode of Congestive Heart Failure | NA (73.82 to NA) |
All participants must have had a baseline LVEF ≥50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The change from baseline LVEF values were reported at every 3 cycles over the course of the study and at the final treatment, worst treatment, and maximum decrease values. The final treatment value was defined as the last LVEF value observed before all study treatment discontinuation. The worst treatment value was defined as the lowest LVEF value observed before all study treatment discontinuation. The maximum decrease value was defined as the largest decrease of LVEF value from baseline, or minimum increase if a participant's post-baseline LVEF measures were all larger than the baseline value.
| Percentage points of LVEF | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Baseline (BL): Absolute Value at Visit | 64.6 ± 6.46 |
| Change from BL at Cycle 3 | -1.1 ± 6.49 |
| Change from BL at Cycle 6 | -1.5 ± 6.60 |
| Change from BL at Cycle 9 | -2.1 ± 6.56 |
| Change from BL at Cycle 12 | -1.9 ± 6.66 |
| Change from BL at Cycle 15 | -2.2 ± 6.50 |
| Change from BL at Cycle 18 | -1.8 ± 6.77 |
| Change from BL at Cycle 21 | -1.9 ± 6.79 |
| Change from BL at Cycle 24 | -1.9 ± 6.93 |
| Change from BL at Cycle 27 | -2.1 ± 6.81 |
| Change from BL at Cycle 30 | -1.8 ± 6.80 |
| Change from BL at Cycle 33 | -1.9 ± 6.97 |
| Change from BL at Cycle 36 | -2.1 ± 6.53 |
| Change from BL at Cycle 39 | -2.1 ± 6.77 |
| Change from BL at Cycle 42 | -1.9 ± 6.52 |
| Change from BL at Cycle 45 | -2.2 ± 6.94 |
| Change from BL at Cycle 48 | -2.1 ± 6.67 |
| Change from BL at Cycle 51 | -1.6 ± 6.75 |
| Change from BL at Cycle 54 | -1.7 ± 6.38 |
| Change from BL at Cycle 57 | -1.7 ± 6.87 |
| Change from BL at Cycle 60 | -1.5 ± 6.46 |
| Change from BL at Cycle 63 | -1.6 ± 7.13 |
| Change from BL at Cycle 66 | -2.0 ± 6.63 |
| Change from BL at Cycle 69 | -1.9 ± 6.45 |
| Change from BL at Cycle 72 | -2.1 ± 6.80 |
| Change from BL at Cycle 75 | -1.5 ± 6.84 |
| Change from BL at Cycle 78 | -1.8 ± 7.41 |
| Change from BL at Cycle 81 | -1.8 ± 6.98 |
| Change from BL at Cycle 84 | -1.6 ± 6.89 |
| Change from BL at Cycle 87 | -1.9 ± 6.31 |
| Change from BL at Cycle 90 | -1.1 ± 6.68 |
| Change from BL at Cycle 93 | -1.6 ± 6.78 |
| Change from BL at Cycle 96 | -1.8 ± 6.33 |
| Change from BL at Cycle 99 | -2.0 ± 7.20 |
| Change from BL at Cycle 102 | -2.5 ± 7.95 |
| Change from BL at Cycle 105 | -2.5 ± 6.86 |
| Change from BL at Cycle 108 | -1.8 ± 8.04 |
| Change from BL at Cycle 111 | -3.3 ± 7.47 |
| Change from BL at Cycle 114 | -1.1 ± 8.12 |
| Change from BL at Cycle 117 | -5.8 ± 7.48 |
| Change from BL at Cycle 120 | -8.6 ± 6.70 |
| Change from BL at Cycle 123 | -9.3 ± 3.51 |
| Change from BL at Cycle 126 | -9.0 ± NA |
| Change from BL at End of Treatment | -3.8 ± 8.34 |
| Change from BL at Day 28 of Follow-Up | -3.2 ± 8.19 |
| Change from BL: Final Treatment Value | -2.0 ± 6.77 |
| Change from BL: Worst Treatment Value | -7.1 ± 6.88 |
| Change from BL: Maximum Decrease Value | -7.7 ± 7.45 |
All participants must have had a baseline LVEF greater than or equal to (≥)50% to enroll in the study; patients with significant cardiac disease or baseline LVEF below 50% were not eligible for this study. The number of participants are reported according to four change from baseline in LVEF value categories over the course of the study: 1) an increase or decrease from baseline LVEF less than (\<)10% points or no change in LVEF; 2) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥10% points to \<15% points; 3) an absolute LVEF value \<45% points and a decrease from baseline LVEF ≥15% points; or 4) an absolute LVEF value ≥45% points and a decrease from baseline LVEF ≥10% points. BL = baseline; Decr. = decrease; Incr. = increase
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Cycle 3 — Incr. or Decr. from BL <10% Points, or No Change | 1190 |
| Cycle 3 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 2 |
| Cycle 3 — LVEF<45% Points and Decr. from BL ≥15% Points | 5 |
| Cycle 3 — LVEF≥45% Points and Decr. from BL ≥10% Points | 114 |
| Cycle 6 — Incr. or Decr. from BL <10% Points, or No Change | 1110 |
| Cycle 6 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 6 — LVEF<45% Points and Decr. from BL ≥15% Points | 2 |
| Cycle 6 — LVEF≥45% Points and Decr. from BL ≥10% Points | 136 |
| Cycle 9 — Incr. or Decr. from BL <10% Points, or No Change | 1005 |
| Cycle 9 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 2 |
| Cycle 9 — LVEF<45% Points and Decr. from BL ≥15% Points | 4 |
| Cycle 9 — LVEF≥45% Points and Decr. from BL ≥10% Points | 139 |
| Cycle 12 — Incr. or Decr. from BL <10% Points, or No Change | 906 |
| Cycle 12 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 12 — LVEF<45% Points and Decr. from BL ≥15% Points | 6 |
| Cycle 12 — LVEF≥45% Points and Decr. from BL ≥10% Points | 116 |
| Cycle 15 — Incr. or Decr. from BL <10% Points, or No Change | 780 |
| Cycle 15 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 3 |
| Cycle 15 — LVEF<45% Points and Decr. from BL ≥15% Points | 6 |
| Cycle 15 — LVEF≥45% Points and Decr. from BL ≥10% Points | 109 |
| Cycle 18 — Incr. or Decr. from BL <10% Points, or No Change | 719 |
| Cycle 18 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 18 — LVEF<45% Points and Decr. from BL ≥15% Points | 5 |
| Cycle 18 — LVEF≥45% Points and Decr. from BL ≥10% Points | 92 |
| Cycle 21 — Incr. or Decr. from BL <10% Points, or No Change | 639 |
| Cycle 21 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 21 — LVEF<45% Points and Decr. from BL ≥15% Points | 4 |
| Cycle 21 — LVEF≥45% Points and Decr. from BL ≥10% Points | 88 |
| Cycle 24 — Incr. or Decr. from BL <10% Points, or No Change | 588 |
| Cycle 24 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 24 — LVEF<45% Points and Decr. from BL ≥15% Points | 2 |
| Cycle 24 — LVEF≥45% Points and Decr. from BL ≥10% Points | 91 |
| Cycle 27 — Incr. or Decr. from BL <10% Points, or No Change | 553 |
| Cycle 27 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 27 — LVEF<45% Points and Decr. from BL ≥15% Points | 2 |
| Cycle 27 — LVEF≥45% Points and Decr. from BL ≥10% Points | 78 |
| Cycle 30 — Incr. or Decr. from BL <10% Points, or No Change | 518 |
| Cycle 30 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 30 — LVEF<45% Points and Decr. from BL ≥15% Points | 1 |
| Cycle 30 — LVEF≥45% Points and Decr. from BL ≥10% Points | 70 |
| Cycle 33 — Incr. or Decr. from BL <10% Points, or No Change | 485 |
| Cycle 33 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 33 — LVEF<45% Points and Decr. from BL ≥15% Points | 1 |
| Cycle 33 — LVEF≥45% Points and Decr. from BL ≥10% Points | 72 |
| Cycle 36 — Incr. or Decr. from BL <10% Points, or No Change | 446 |
| Cycle 36 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 36 — LVEF<45% Points and Decr. from BL ≥15% Points | 1 |
| Cycle 36 — LVEF≥45% Points and Decr. from BL ≥10% Points | 62 |
| Cycle 39 — Incr. or Decr. from BL <10% Points, or No Change | 414 |
| Cycle 39 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 1 |
| Cycle 39 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 39 — LVEF≥45% Points and Decr. from BL ≥10% Points | 65 |
| Cycle 42 — Incr. or Decr. from BL <10% Points, or No Change | 405 |
| Cycle 42 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 42 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 42 — LVEF≥45% Points and Decr. from BL ≥10% Points | 46 |
| Cycle 45 — Incr. or Decr. from BL <10% Points, or No Change | 358 |
| Cycle 45 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 45 — LVEF<45% Points and Decr. from BL ≥15% Points | 1 |
| Cycle 45 — LVEF≥45% Points and Decr. from BL ≥10% Points | 69 |
| Cycle 48 — Incr. or Decr. from BL <10% Points, or No Change | 340 |
| Cycle 48 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 48 — LVEF<45% Points and Decr. from BL ≥15% Points | 1 |
| Cycle 48 — LVEF≥45% Points and Decr. from BL ≥10% Points | 49 |
| Cycle 51 — Incr. or Decr. from BL <10% Points, or No Change | 314 |
| Cycle 51 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 51 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 51 — LVEF≥45% Points and Decr. from BL ≥10% Points | 43 |
| Cycle 54 — Incr. or Decr. from BL <10% Points, or No Change | 292 |
| Cycle 54 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 54 — LVEF<45% Points and Decr. from BL ≥15% Points | 3 |
| Cycle 54 — LVEF≥45% Points and Decr. from BL ≥10% Points | 30 |
| Cycle 57 — Incr. or Decr. from BL <10% Points, or No Change | 291 |
| Cycle 57 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 57 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 57 — LVEF≥45% Points and Decr. from BL ≥10% Points | 41 |
| Cycle 60 — Incr. or Decr. from BL <10% Points, or No Change | 284 |
| Cycle 60 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 60 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 60 — LVEF≥45% Points and Decr. from BL ≥10% Points | 29 |
| Cycle 63 — Incr. or Decr. from BL <10% Points, or No Change | 263 |
| Cycle 63 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 63 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 63 — LVEF≥45% Points and Decr. from BL ≥10% Points | 39 |
| Cycle 66 — Incr. or Decr. from BL <10% Points, or No Change | 249 |
| Cycle 66 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 66 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 66 — LVEF≥45% Points and Decr. from BL ≥10% Points | 35 |
| Cycle 69 — Incr. or Decr. from BL <10% Points, or No Change | 237 |
| Cycle 69 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 69 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 69 — LVEF≥45% Points and Decr. from BL ≥10% Points | 33 |
| Cycle 72 — Incr. or Decr. from BL <10% Points, or No Change | 224 |
| Cycle 72 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 72 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 72 — LVEF≥45% Points and Decr. from BL ≥10% Points | 35 |
| Cycle 75 — Incr. or Decr. from BL <10% Points, or No Change | 224 |
| Cycle 75 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 75 — LVEF<45% Points and Decr. from BL ≥15% Points | 1 |
| Cycle 75 — LVEF≥45% Points and Decr. from BL ≥10% Points | 29 |
| Cycle 78 — Incr. or Decr. from BL <10% Points, or No Change | 214 |
| Cycle 78 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 78 — LVEF<45% Points and Decr. from BL ≥15% Points | 2 |
| Cycle 78 — LVEF≥45% Points and Decr. from BL ≥10% Points | 29 |
| Cycle 81 — Incr. or Decr. from BL <10% Points, or No Change | 196 |
| Cycle 81 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 81 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 81 — LVEF≥45% Points and Decr. from BL ≥10% Points | 30 |
| Cycle 84 — Incr. or Decr. from BL <10% Points, or No Change | 192 |
| Cycle 84 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 84 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 84 — LVEF≥45% Points and Decr. from BL ≥10% Points | 23 |
| Cycle 87 — Incr. or Decr. from BL <10% Points, or No Change | 174 |
| Cycle 87 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 87 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 87 — LVEF≥45% Points and Decr. from BL ≥10% Points | 22 |
| Cycle 90 — Incr. or Decr. from BL <10% Points, or No Change | 161 |
| Cycle 90 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 90 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 90 — LVEF≥45% Points and Decr. from BL ≥10% Points | 16 |
| Cycle 93 — Incr. or Decr. from BL <10% Points, or No Change | 140 |
| Cycle 93 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 93 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 93 — LVEF≥45% Points and Decr. from BL ≥10% Points | 16 |
| Cycle 96 — Incr. or Decr. from BL <10% Points, or No Change | 115 |
| Cycle 96 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 96 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 96 — LVEF≥45% Points and Decr. from BL ≥10% Points | 13 |
| Cycle 99 — Incr. or Decr. from BL <10% Points, or No Change | 92 |
| Cycle 99 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 99 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 99 — LVEF≥45% Points and Decr. from BL ≥10% Points | 14 |
| Cycle 102 — Incr. or Decr. from BL <10% Points, or No Change | 68 |
| Cycle 102 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 102 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 102 — LVEF≥45% Points and Decr. from BL ≥10% Points | 14 |
| Cycle 105 — Incr. or Decr. from BL <10% Points, or No Change | 56 |
| Cycle 105 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 105 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 105 — LVEF≥45% Points and Decr. from BL ≥10% Points | 9 |
| Cycle 108 — Incr. or Decr. from BL <10% Points, or No Change | 41 |
| Cycle 108 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 108 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 108 — LVEF≥45% Points and Decr. from BL ≥10% Points | 8 |
| Cycle 111 — Incr. or Decr. from BL <10% Points, or No Change | 34 |
| Cycle 111 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 111 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 111 — LVEF≥45% Points and Decr. from BL ≥10% Points | 8 |
| Cycle 114 — Incr. or Decr. from BL <10% Points, or No Change | 19 |
| Cycle 114 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 114 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 114 — LVEF≥45% Points and Decr. from BL ≥10% Points | 4 |
| Cycle 117 — Incr. or Decr. from BL <10% Points, or No Change | 11 |
| Cycle 117 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 117 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 117 — LVEF≥45% Points and Decr. from BL ≥10% Points | 6 |
| Cycle 120 — Incr. or Decr. from BL <10% Points, or No Change | 4 |
| Cycle 120 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 120 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 120 — LVEF≥45% Points and Decr. from BL ≥10% Points | 3 |
| Cycle 123 — Incr. or Decr. from BL <10% Points, or No Change | 2 |
| Cycle 123 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 123 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 123 — LVEF≥45% Points and Decr. from BL ≥10% Points | 1 |
| Cycle 126 — Incr. or Decr. from BL <10% Points, or No Change | 1 |
| Cycle 126 — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 0 |
| Cycle 126 — LVEF<45% Points and Decr. from BL ≥15% Points | 0 |
| Cycle 126 — LVEF≥45% Points and Decr. from BL ≥10% Points | 0 |
| End of Treatment — Incr. or Decr. from BL <10% Points, or No Change | 431 |
| End of Treatment — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 2 |
| End of Treatment — LVEF<45% Points and Decr. from BL ≥15% Points | 26 |
| End of Treatment — LVEF≥45% Points and Decr. from BL ≥10% Points | 87 |
| Day 28 of Follow-Up — Incr. or Decr. from BL <10% Points, or No Change | 472 |
| Day 28 of Follow-Up — LVEF<45% Points and Decr. from BL ≥10%-<15% Points | 4 |
| Day 28 of Follow-Up — LVEF<45% Points and Decr. from BL ≥15% Points | 22 |
| Day 28 of Follow-Up — LVEF≥45% Points and Decr. from BL ≥10% Points | 86 |
Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Absolute Neutrophil Count: Normal to Normal | 844 |
| Absolute Neutrophil Count: Normal to Grade 1 | 232 |
| Absolute Neutrophil Count: Normal to Grade 2 | 169 |
| Absolute Neutrophil Count: Normal to Grade 3 | 45 |
| Absolute Neutrophil Count: Normal to Grade 4 | 27 |
| Absolute Neutrophil Count: Normal to Missing | 27 |
| Absolute Neutrophil Count: Grade 1 to Normal | 3 |
| Absolute Neutrophil Count: Grade 1 to 1 | 11 |
| Absolute Neutrophil Count: Grade 1 to 2 | 14 |
| Absolute Neutrophil Count: Grade 1 to 3 | 3 |
| Absolute Neutrophil Count: Grade 2 to 1 | 2 |
| Absolute Neutrophil Count: Missing to Normal | 21 |
| Absolute Neutrophil Count: Missing to Grade 1 | 2 |
| Absolute Neutrophil Count: Missing to Grade 2 | 3 |
| Absolute Neutrophil Count: Missing to Grade 4 | 1 |
| Absolute Neutrophil Count: Missing to Missing | 32 |
| Hemoglobin (High): Normal to Normal | 1327 |
| Hemoglobin (High): Normal to Grade 1 | 29 |
| Hemoglobin (High): Normal to Grade 3 | 1 |
| Hemoglobin (High): Normal to Missing | 26 |
| Hemoglobin (High): Grade 1 to Normal | 28 |
| Hemoglobin (High): Grade 1 to 1 | 5 |
| Hemoglobin (High): Grade 1 to Missing | 2 |
| Hemoglobin (High): Grade 2 to Normal | 1 |
| Hemoglobin (High): Missing to Normal | 14 |
| Hemoglobin (High): Missing to Missing | 3 |
| Hemoglobin (Low): Normal to Normal | 257 |
| Hemoglobin (Low): Normal to Grade 1 | 648 |
| Hemoglobin (Low): Normal to Grade 2 | 198 |
| Hemoglobin (Low): Normal to Grade 3 | 10 |
| Hemoglobin (Low): Normal to Missing | 21 |
| Hemoglobin (Low): Grade 1 to Normal | 2 |
| Hemoglobin (Low): Grade 1 to 1 | 109 |
| Hemoglobin (Low): Grade 1 to 2 | 128 |
| Hemoglobin (Low): Grade 1 to 3 | 12 |
| Hemoglobin (Low): Grade 1 to Missing | 4 |
| Hemoglobin (Low): Grade 2 to 1 | 5 |
| Hemoglobin (Low): Grade 2 to 2 | 18 |
| Hemoglobin (Low): Grade 2 to 3 | 3 |
| Hemoglobin (Low): Grade 2 to Missing | 3 |
| Hemoglobin (Low): Grade 3 to 1 | 1 |
| Hemoglobin (Low): Missing to Normal | 3 |
| Hemoglobin (Low): Missing to Grade 1 | 7 |
| Hemoglobin (Low): Missing to Grade 2 | 4 |
| Hemoglobin (Low): Missing to Missing | 3 |
| Lymphocytes (High): Normal to Normal | 1251 |
| Lymphocytes (High): Normal to Grade 2 | 111 |
| Lymphocytes (High): Normal to Grade 3 | 8 |
| Lymphocytes (High): Normal to Missing | 28 |
| Lymphocytes (High): Grade 2 to Normal | 4 |
| Lymphocytes (High): Grade 2 to 2 | 10 |
| Lymphocytes (High): Grade 2 to 3 | 2 |
| Lymphocytes (High): Grade 3 to Normal | 1 |
| Lymphocytes (High): Grade 3 to 3 | 2 |
| Lymphocytes (High): Missing to Normal | 15 |
| Lymphocytes (High): Missing to Grade 2 | 2 |
| Lymphocytes (High): Missing to Missing | 2 |
| Lymphocytes (Low): Normal to Normal | 565 |
| Lymphocytes (Low): Normal to Grade 1 | 255 |
| Lymphocytes (Low): Normal to Grade 2 | 210 |
| Lymphocytes (Low): Normal to Grade 3 | 76 |
| Lymphocytes (Low): Normal to Grade 4 | 18 |
| Lymphocytes (Low): Normal to Missing | 19 |
| Lymphocytes (Low): Grade 1 to Normal | 11 |
| Lymphocytes (Low): Grade 1 to 1 | 54 |
| Lymphocytes (Low): Grade 1 to 2 | 51 |
| Lymphocytes (Low): Grade 1 to 3 | 18 |
| Lymphocytes (Low): Grade 1 to 4 | 6 |
| Lymphocytes (Low): Grade 1 to Missing | 5 |
| Lymphocytes (Low): Grade 2 to Normal | 12 |
| Lymphocytes (Low): Grade 2 to 1 | 8 |
| Lymphocytes (Low): Grade 2 to 2 | 37 |
| Lymphocytes (Low): Grade 2 to 3 | 19 |
| Lymphocytes (Low): Grade 2 to 4 | 1 |
| Lymphocytes (Low): Grade 2 to Missing | 2 |
| Lymphocytes (Low): Grade 3 to 1 | 3 |
| Lymphocytes (Low): Grade 3 to 2 | 8 |
| Lymphocytes (Low): Grade 3 to 3 | 14 |
| Lymphocytes (Low): Grade 3 to 4 | 2 |
| Lymphocytes (Low): Grade 3 to Missing | 1 |
| Lymphocytes (Low): Grade 4 to 2 | 1 |
| Lymphocytes (Low): Grade 4 to 3 | 3 |
| Lymphocytes (Low): Grade 4 to 4 | 16 |
| Lymphocytes (Low): Grade 4 to Missing | 1 |
| Lymphocytes (Low): Missing to Normal | 11 |
| Lymphocytes (Low): Missing to Grade 1 | 3 |
| Lymphocytes (Low): Missing to Grade 2 | 3 |
| Lymphocytes (Low): Missing to Grade 3 | 1 |
| Lymphocytes (Low): Missing to Missing | 2 |
| Platelet Count: Normal to Normal | 1222 |
| Platelet Count: Normal to Grade 1 | 149 |
| Platelet Count: Normal to Grade 3 | 1 |
| Platelet Count: Normal to Grade 4 | 2 |
| Platelet Count: Normal to Missing | 26 |
| Platelet Count: Grade 1 to Normal | 15 |
| Platelet Count: Grade 1 to 1 | 16 |
| Platelet Count: Grade 1 to 2 | 1 |
| Platelet Count: Grade 1 to Missing | 2 |
| Platelet Count: Missing to Normal | 1 |
| Platelet Count: Missing to Grade 1 | 1 |
| White Blood Cells (High): Normal to Normal | 1391 |
| White Blood Cells (High): Normal to Missing | 29 |
| White Blood Cells (High): Missing to Normal | 14 |
| White Blood Cells (High): Missing to Missing | 2 |
| White Blood Cells (Low): Normal to Normal | 702 |
| White Blood Cells (Low): Normal to Grade 1 | 392 |
| White Blood Cells (Low): Normal to Grade 2 | 190 |
| White Blood Cells (Low): Normal to Grade 3 | 29 |
| White Blood Cells (Low): Normal to Grade 4 | 6 |
| White Blood Cells (Low): Normal to Missing | 29 |
| White Blood Cells (Low): Grade 1 to Normal | 4 |
| White Blood Cells (Low): Grade 1 to 1 | 20 |
| White Blood Cells (Low): Grade 1 to 2 | 33 |
| White Blood Cells (Low): Grade 1 to 3 | 4 |
| White Blood Cells (Low): Grade 2 to Normal | 2 |
| White Blood Cells (Low): Grade 2 to 1 | 4 |
| White Blood Cells (Low): Grade 2 to 2 | 3 |
| White Blood Cells (Low): Grade 3 to Normal | 1 |
| White Blood Cells (Low): Grade 3 to 3 | 1 |
| White Blood Cells (Low): Missing to Normal | 9 |
| White Blood Cells (Low): Missing to Grade 1 | 3 |
| White Blood Cells (Low): Missing to Grade 2 | 1 |
| White Blood Cells (Low): Missing to Grade 3 | 1 |
| White Blood Cells (Low): Missing to Missing | 2 |
| International Normalized Ratio: Normal to Normal | 17 |
| International Normalized Ratio: Normal to Grade 1 | 52 |
| International Normalized Ratio: Normal to Grade 2 | 1 |
| International Normalized Ratio: Normal to Missing | 3 |
| International Normalized Ratio: Grade 1 to Normal | 1 |
| International Normalized Ratio: Grade 2 to 3 | 1 |
| International Normalized Ratio: Missing to Normal | 424 |
| International Normalized Ratio: Missing to Grade 1 | 615 |
| International Normalized Ratio: Missing to Grade 2 | 23 |
| International Normalized Ratio: Missing to Grade 3 | 14 |
| International Normalized Ratio: Missing to Missing | 285 |
Clinical laboratory tests for hematology and coagulation parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Basophils (High): Normal to Normal | 1020 |
| Basophils (High): Normal to Low | 3 |
| Basophils (High): Normal to High | 261 |
| Basophils (High): Low to Normal | 16 |
| Basophils (High): Low to Low | 1 |
| Basophils (High): Low to High | 5 |
| Basophils (High): High to Normal | 11 |
| Basophils (High): High to High | 38 |
| Basophils (High): Missing to Normal | 21 |
| Basophils (High): Missing to High | 7 |
| Basophils (High): Missing to Missing | 53 |
| Basophils (Low): Normal to Normal | 1206 |
| Basophils (Low): Normal to Low | 77 |
| Basophils (Low): Normal to High | 1 |
| Basophils (Low): Low to Normal | 3 |
| Basophils (Low): Low to Low | 18 |
| Basophils (Low): Low to Missing | 1 |
| Basophils (Low): High to Normal | 36 |
| Basophils (Low): High to Low | 5 |
| Basophils (Low): High to High | 8 |
| Basophils (Low): Missing to Normal | 40 |
| Basophils (Low): Missing to Low | 3 |
| Basophils (Low): Missing to High | 1 |
| Basophils (Low): Missing to Missing | 37 |
| Eosinophils (High): Normal to Normal | 904 |
| Eosinophils (High): Normal to Low | 13 |
| Eosinophils (High): Normal to High | 283 |
| Eosinophils (High): Low to Normal | 66 |
| Eosinophils (High): Low to Low | 13 |
| Eosinophils (High): Low to High | 36 |
| Eosinophils (High): High to Normal | 11 |
| Eosinophils (High): High to High | 35 |
| Eosinophils (High): Missing to Normal | 17 |
| Eosinophils (High): Missing to Low | 1 |
| Eosinophils (High): Missing to High | 7 |
| Eosinophils (High): Missing to Missing | 50 |
| Eosinophils (Low): Normal to Normal | 810 |
| Eosinophils (Low): Normal to Low | 390 |
| Eosinophils (Low): Low to Normal | 13 |
| Eosinophils (Low): Low to Low | 101 |
| Eosinophils (Low): Low to High | 1 |
| Eosinophils (Low): High to Normal | 28 |
| Eosinophils (Low): High to Low | 13 |
| Eosinophils (Low): High to High | 5 |
| Eosinophils (Low): Missing to Normal | 37 |
| Eosinophils (Low): Missing to Low | 10 |
| Eosinophils (Low): Missing to Missing | 28 |
| Hematocrit (High): Normal to Normal | 953 |
| Hematocrit (High): Normal to Low | 47 |
| Hematocrit (High): Normal to High | 58 |
| Hematocrit (High): Normal to Missing | 4 |
| Hematocrit (High): Low to Normal | 201 |
| Hematocrit (High): Low to Low | 97 |
| Hematocrit (High): Low to High | 10 |
| Hematocrit (High): Low to Missing | 2 |
| Hematocrit (High): High to Normal | 17 |
| Hematocrit (High): High to High | 12 |
| Hematocrit (High): Missing to Normal | 15 |
| Hematocrit (High): Missing to High | 1 |
| Hematocrit (High): Missing to Missing | 19 |
| Hematocrit (Low): Normal to Normal | 223 |
| Hematocrit (Low): Normal to Low | 837 |
| Hematocrit (Low): Normal to Missing | 2 |
| Hematocrit (Low): Low to Normal | 5 |
| Hematocrit (Low): Low to Low | 305 |
| Hematocrit (Low): High to Normal | 13 |
| Hematocrit (Low): High to Low | 16 |
| Hematocrit (Low): Missing to Normal | 3 |
| Hematocrit (Low): Missing to Low | 12 |
| Hematocrit (Low): Missing to Missing | 20 |
| Monocytes (High): Normal to Normal | 802 |
| Monocytes (High): Normal to Low | 3 |
| Monocytes (High): Normal to High | 365 |
| Monocytes (High): Low to Normal | 58 |
| Monocytes (High): Low to Low | 6 |
| Monocytes (High): Low to High | 17 |
| Monocytes (High): High to Normal | 29 |
| Monocytes (High): High to Low | 1 |
| Monocytes (High): High to High | 82 |
| Monocytes (High): Missing to Normal | 12 |
| Monocytes (High): Missing to High | 8 |
| Monocytes (High): Missing to Missing | 53 |
| Monocytes (Low): Normal to Normal | 747 |
| Monocytes (Low): Normal to Low | 420 |
| Monocytes (Low): Normal to High | 3 |
| Monocytes (Low): Low to Normal | 11 |
| Monocytes (Low): Low to Low | 70 |
| Monocytes (Low): High to Normal | 64 |
| Monocytes (Low): High to Low | 40 |
| Monocytes (Low): High to High | 8 |
| Monocytes (Low): Missing to Normal | 13 |
| Monocytes (Low): Missing to Low | 10 |
| Monocytes (Low): Missing to High | 5 |
| Monocytes (Low): Missing to Missing | 45 |
| Red Blood Cells (High): Normal to Normal | 975 |
| Red Blood Cells (High): Normal to Low | 31 |
| Red Blood Cells (High): Normal to High | 111 |
| Red Blood Cells (High): Low to Normal | 131 |
| Red Blood Cells (High): Low to Low | 61 |
| Red Blood Cells (High): Low to High | 15 |
| Red Blood Cells (High): High to Normal | 22 |
| Red Blood Cells (High): High to High | 45 |
| Red Blood Cells (High): Missing to Normal | 18 |
| Red Blood Cells (High): Missing to Low | 2 |
| Red Blood Cells (High): Missing to High | 2 |
| Red Blood Cells (High): Missing to Missing | 23 |
| Red Blood Cells (Low): Normal to Normal | 350 |
| Red Blood Cells (Low): Normal to Low | 767 |
| Red Blood Cells (Low): Low to Normal | 10 |
| Red Blood Cells (Low): Low to Low | 197 |
| Red Blood Cells (Low): High to Normal | 44 |
| Red Blood Cells (Low): High to Low | 21 |
| Red Blood Cells (Low): High to High | 2 |
| Red Blood Cells (Low): Missing to Normal | 6 |
| Red Blood Cells (Low): Missing to Low | 16 |
| Red Blood Cells (Low): Missing to Missing | 23 |
| PTT (High): Normal to Normal | 46 |
| PTT (High): Normal to Low | 1 |
| PTT (High): Normal to High | 15 |
| PTT (High): Low to Normal | 19 |
| PTT (High): Low to Low | 1 |
| PTT (High): Low to High | 1 |
| PTT (High): High to High | 1 |
| PTT (High): Missing to Normal | 19 |
| PTT (High): Missing to Low | 5 |
| PTT (High): Missing to High | 9 |
| PTT (High): Missing to Missing | 1319 |
| PTT (Low): Normal to Normal | 46 |
| PTT (Low): Normal to Low | 16 |
| PTT (Low): Low to Normal | 3 |
| PTT (Low): Low to Low | 18 |
| PTT (Low): High to Normal | 1 |
| PTT (Low): Missing to Normal | 20 |
| PTT (Low): Missing to Low | 6 |
| PTT (Low): Missing to High | 5 |
| PTT (Low): Missing to Missing | 1321 |
Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on NCI-CTC v4.0 from Grades 1 (least severe) to 4 (most severe). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Alanine Aminotransferase: Normal to Normal | 610 |
| Alanine Aminotransferase: Normal to Grade 1 | 425 |
| Alanine Aminotransferase: Normal to Grade 2 | 26 |
| Alanine Aminotransferase: Normal to Grade 3 | 19 |
| Alanine Aminotransferase: Normal to Missing | 25 |
| Alanine Aminotransferase: Grade 1 to Normal | 75 |
| Alanine Aminotransferase: Grade 1 to 1 | 151 |
| Alanine Aminotransferase: Grade 1 to 2 | 26 |
| Alanine Aminotransferase: Grade 1 to 3 | 14 |
| Alanine Aminotransferase: Grade 1 to Missing | 6 |
| Alanine Aminotransferase: Grade 2 to Normal | 8 |
| Alanine Aminotransferase: Grade 2 to 1 | 28 |
| Alanine Aminotransferase: Grade 2 to 2 | 5 |
| Alanine Aminotransferase: Grade 2 to 3 | 1 |
| Alanine Aminotransferase: Grade 3 to 1 | 2 |
| Alanine Aminotransferase: Missing to Normal | 7 |
| Alanine Aminotransferase: Missing to Grade 1 | 4 |
| Alanine Aminotransferase: Missing to Grade 2 | 1 |
| Alanine Aminotransferase: Missing to Missing | 3 |
| Aspartate Aminotransferase: Normal to Normal | 562 |
| Aspartate Aminotransferase: Normal to Grade 1 | 386 |
| Aspartate Aminotransferase: Normal to Grade 2 | 22 |
| Aspartate Aminotransferase: Normal to Grade 3 | 9 |
| Aspartate Aminotransferase: Normal to Missing | 15 |
| Aspartate Aminotransferase: Grade 1 to Normal | 120 |
| Aspartate Aminotransferase: Grade 1 to 1 | 187 |
| Aspartate Aminotransferase: Grade 1 to 2 | 24 |
| Aspartate Aminotransferase: Grade 1 to 3 | 9 |
| Aspartate Aminotransferase: Grade 1 to Missing | 14 |
| Aspartate Aminotransferase: Grade 2 to Normal | 13 |
| Aspartate Aminotransferase: Grade 2 to 1 | 29 |
| Aspartate Aminotransferase: Grade 2 to 2 | 3 |
| Aspartate Aminotransferase: Grade 2 to Missing | 3 |
| Aspartate Aminotransferase: Grade 3 to Normal | 2 |
| Aspartate Aminotransferase: Grade 3 to 1 | 7 |
| Aspartate Aminotransferase: Grade 3 to Missing | 1 |
| Aspartate Aminotransferase: Missing to Normal | 13 |
| Aspartate Aminotransferase: Missing to Grade 1 | 9 |
| Aspartate Aminotransferase: Missing to Grade 2 | 2 |
| Aspartate Aminotransferase: Missing to Missing | 6 |
| Albumin: Normal to Normal | 785 |
| Albumin: Normal to Grade 1 | 357 |
| Albumin: Normal to Grade 2 | 86 |
| Albumin: Normal to Grade 3 | 10 |
| Albumin: Normal to Missing | 23 |
| Albumin: Grade 1 to Normal | 13 |
| Albumin: Grade 1 to 1 | 43 |
| Albumin: Grade 1 to 2 | 35 |
| Albumin: Grade 1 to 3 | 1 |
| Albumin: Grade 1 to Missing | 7 |
| Albumin: Grade 2 to Normal | 3 |
| Albumin: Grade 2 to 1 | 5 |
| Albumin: Grade 2 to 2 | 8 |
| Albumin: Grade 2 to 3 | 2 |
| Albumin: Grade 2 to Missing | 2 |
| Albumin: Grade 3 to 2 | 1 |
| Albumin: Grade 3 to Missing | 1 |
| Albumin: Missing to Normal | 28 |
| Albumin: Missing to Grade 1 | 14 |
| Albumin: Missing to Grade 2 | 6 |
| Albumin: Missing to Missing | 6 |
| Alkaline Phosphatase: Normal to Normal | 605 |
| Alkaline Phosphatase: Normal to Grade 1 | 329 |
| Alkaline Phosphatase: Normal to Grade 2 | 14 |
| Alkaline Phosphatase: Normal to Grade 3 | 2 |
| Alkaline Phosphatase: Normal to Missing | 18 |
| Alkaline Phosphatase: Grade 1 to Normal | 44 |
| Alkaline Phosphatase: Grade 1 to 1 | 241 |
| Alkaline Phosphatase: Grade 1 to 2 | 72 |
| Alkaline Phosphatase: Grade 1 to 3 | 15 |
| Alkaline Phosphatase: Grade 1 to Missing | 6 |
| Alkaline Phosphatase: Grade 2 to Normal | 2 |
| Alkaline Phosphatase: Grade 2 to 1 | 21 |
| Alkaline Phosphatase: Grade 2 to 2 | 24 |
| Alkaline Phosphatase: Grade 2 to 3 | 14 |
| Alkaline Phosphatase: Grade 2 to Missing | 8 |
| Alkaline Phosphatase: Grade 3 to 1 | 2 |
| Alkaline Phosphatase: Grade 3 to 2 | 1 |
| Alkaline Phosphatase: Grade 3 to 3 | 4 |
| Alkaline Phosphatase: Missing to Normal | 7 |
| Alkaline Phosphatase: Missing to Grade 1 | 3 |
| Alkaline Phosphatase: Missing to Grade 3 | 1 |
| Alkaline Phosphatase: Missing to Missing | 3 |
| Calcium (High): Normal to Normal | 1060 |
| Calcium (High): Normal to Grade 1 | 192 |
| Calcium (High): Normal to Grade 2 | 2 |
| Calcium (High): Normal to Grade 3 | 1 |
| Calcium (High): Normal to Grade 4 | 1 |
| Calcium (High): Normal to Missing | 26 |
| Calcium (High): Grade 1 to Normal | 47 |
| Calcium (High): Grade 1 to 1 | 47 |
| Calcium (High): Grade 1 to 2 | 1 |
| Calcium (High): Grade 1 to 3 | 1 |
| Calcium (High): Grade 1 to Missing | 5 |
| Calcium (High): Grade 2 to Normal | 1 |
| Calcium (High): Grade 2 to 1 | 1 |
| Calcium (High): Grade 2 to 2 | 1 |
| Calcium (High): Grade 3 to Normal | 2 |
| Calcium (High): Grade 3 to 1 | 1 |
| Calcium (High): Grade 3 to 2 | 1 |
| Calcium (High): Grade 4 to Normal | 1 |
| Calcium (High): Missing to Normal | 32 |
| Calcium (High): Missing to Grade 1 | 3 |
| Calcium (High): Missing to Missing | 10 |
| Calcium (Low): Normal to Normal | 786 |
| Calcium (Low): Normal to Grade 1 | 378 |
| Calcium (Low): Normal to Grade 2 | 117 |
| Calcium (Low): Normal to Grade 3 | 18 |
| Calcium (Low): Normal to Missing | 30 |
| Calcium (Low): Grade 1 to Normal | 5 |
| Calcium (Low): Grade 1 to 1 | 31 |
| Calcium (Low): Grade 1 to 2 | 12 |
| Calcium (Low): Grade 1 to 3 | 2 |
| Calcium (Low): Grade 1 to Missing | 1 |
| Calcium (Low): Grade 2 to Normal | 5 |
| Calcium (Low): Grade 2 to 1 | 1 |
| Calcium (Low): Grade 2 to 2 | 4 |
| Calcium (Low): Grade 3 to 3 | 1 |
| Calcium (Low): Missing to Normal | 20 |
| Calcium (Low): Missing to Grade 1 | 11 |
| Calcium (Low): Missing to Grade 2 | 4 |
| Calcium (Low): Missing to Missing | 10 |
| Creatinine: Normal to Normal | 176 |
| Creatinine: Normal to Grade 1 | 960 |
| Creatinine: Normal to Grade 2 | 175 |
| Creatinine: Normal to Grade 3 | 5 |
| Creatinine: Normal to Grade 4 | 5 |
| Creatinine: Normal to Missing | 26 |
| Creatinine: Grade 1 to Normal | 12 |
| Creatinine: Grade 1 to 1 | 38 |
| Creatinine: Grade 1 to 2 | 8 |
| Creatinine: Grade 1 to Missing | 3 |
| Creatinine: Grade 2 to 2 | 3 |
| Creatinine: Grade 2 to 3 | 1 |
| Creatinine: Grade 2 to Missing | 1 |
| Creatinine: Missing to Normal | 11 |
| Creatinine: Missing to Grade 1 | 6 |
| Creatinine: Missing to Missing | 6 |
| Gamma-Glutamyl Transpeptidase: Normal to Normal | 498 |
| Gamma-Glutamyl Transpeptidase: Normal to Grade 1 | 227 |
| Gamma-Glutamyl Transpeptidase: Normal to Grade 2 | 39 |
| Gamma-Glutamyl Transpeptidase: Normal to Grade 3 | 15 |
| Gamma-Glutamyl Transpeptidase: Normal to Missing | 12 |
| Gamma-Glutamyl Transpeptidase: Grade 1 to Normal | 64 |
| Gamma-Glutamyl Transpeptidase: Grade 1 to 1 | 187 |
| Gamma-Glutamyl Transpeptidase: Grade 1 to 2 | 75 |
| Gamma-Glutamyl Transpeptidase: Grade 1 to 3 | 20 |
| Gamma-Glutamyl Transpeptidase: Grade 1 to Missing | 7 |
| Gamma-Glutamyl Transpeptidase: Grade 2 to Normal | 5 |
| Gamma-Glutamyl Transpeptidase: Grade 2 to 1 | 52 |
| Gamma-Glutamyl Transpeptidase: Grade 2 to 2 | 45 |
| Gamma-Glutamyl Transpeptidase: Grade 2 to 3 | 21 |
| Gamma-Glutamyl Transpeptidase: Grade 2 to Missing | 5 |
| Gamma-Glutamyl Transpeptidase: Grade 3 to Normal | 2 |
| Gamma-Glutamyl Transpeptidase: Grade 3 to 1 | 15 |
| Gamma-Glutamyl Transpeptidase: Grade 3 to 2 | 38 |
| Gamma-Glutamyl Transpeptidase: Grade 3 to 3 | 47 |
| Gamma-Glutamyl Transpeptidase: Grade 3 to Missing | 4 |
| Gamma-Glutamyl Transpeptidase: Missing to Normal | 14 |
| Gamma-Glutamyl Transpeptidase: Missing to Grade 1 | 7 |
| Gamma-Glutamyl Transpeptidase: Missing to Grade 2 | 10 |
| Gamma-Glutamyl Transpeptidase: Missing to Grade 3 | 18 |
| Gamma-Glutamyl Transpeptidase: Missing to Missing | 9 |
| Glucose (High): Normal to Normal | 340 |
| Glucose (High): Normal to Grade 1 | 534 |
| Glucose (High): Normal to Grade 2 | 115 |
| Glucose (High): Normal to Missing | 21 |
| Glucose (High): Grade 1 to Normal | 28 |
| Glucose (High): Grade 1 to 1 | 190 |
| Glucose (High): Grade 1 to 2 | 74 |
| Glucose (High): Grade 1 to Missing | 9 |
| Glucose (High): Grade 2 to Normal | 2 |
| Glucose (High): Grade 2 to 1 | 13 |
| Glucose (High): Grade 2 to 2 | 10 |
| Glucose (High): Grade 2 to Missing | 3 |
| Glucose (High): Missing to Normal | 20 |
| Glucose (High): Missing to Grade 1 | 30 |
| Glucose (High): Missing to Grade 2 | 40 |
| Glucose (High): Missing to Missing | 7 |
| Glucose (Low): Normal to Normal | 1061 |
| Glucose (Low): Normal to Grade 1 | 173 |
| Glucose (Low): Normal to Grade 2 | 19 |
| Glucose (Low): Normal to Grade 3 | 4 |
| Glucose (Low): Normal to Grade 4 | 5 |
| Glucose (Low): Normal to Missing | 33 |
| Glucose (Low): Grade 1 to Normal | 8 |
| Glucose (Low): Grade 1 to 1 | 24 |
| Glucose (Low): Grade 1 to 2 | 3 |
| Glucose (Low): Grade 1 to 3 | 1 |
| Glucose (Low): Grade 1 to 4 | 1 |
| Glucose (Low): Grade 2 to Normal | 1 |
| Glucose (Low): Missing to Normal | 69 |
| Glucose (Low): Missing to Grade 1 | 16 |
| Glucose (Low): Missing to Grade 2 | 2 |
| Glucose (Low): Missing to Grade 3 | 1 |
| Glucose (Low): Missing to Missing | 15 |
| Magnesium (High): Normal to Normal | 1100 |
| Magnesium (High): Normal to Grade 1 | 122 |
| Magnesium (High): Normal to Grade 3 | 38 |
| Magnesium (High): Normal to Grade 4 | 6 |
| Magnesium (High): Normal to Missing | 31 |
| Magnesium (High): Grade 1 to Normal | 12 |
| Magnesium (High): Grade 1 to 1 | 7 |
| Magnesium (High): Grade 3 to Normal | 2 |
| Magnesium (High): Grade 3 to 3 | 2 |
| Magnesium (High): Grade 4 to Normal | 1 |
| Magnesium (High): Grade 4 to 4 | 1 |
| Magnesium (High): Missing to Normal | 85 |
| Magnesium (High): Missing to Grade 1 | 12 |
| Magnesium (High): Missing to Grade 3 | 6 |
| Magnesium (High): Missing to Missing | 11 |
| Magnesium (Low): Normal to Normal | 857 |
| Magnesium (Low): Normal to Grade 1 | 319 |
| Magnesium (Low): Normal to Grade 2 | 28 |
| Magnesium (Low): Normal to Grade 3 | 9 |
| Magnesium (Low): Normal to Grade 4 | 3 |
| Magnesium (Low): Normal to Missing | 28 |
| Magnesium (Low): Grade 1 to Normal | 9 |
| Magnesium (Low): Grade 1 to 1 | 55 |
| Magnesium (Low): Grade 1 to 2 | 7 |
| Magnesium (Low): Grade 1 to 3 | 3 |
| Magnesium (Low): Grade 1 to Missing | 3 |
| Magnesium (Low): Grade 4 to 4 | 1 |
| Magnesium (Low): Missing to Normal | 81 |
| Magnesium (Low): Missing to Grade 1 | 19 |
| Magnesium (Low): Missing to Grade 2 | 1 |
| Magnesium (Low): Missing to Grade 3 | 1 |
| Magnesium (Low): Missing to Grade 4 | 1 |
| Magnesium (Low): Missing to Missing | 11 |
| Potassium (High): Normal to Normal | 1051 |
| Potassium (High): Normal to Grade 1 | 183 |
| Potassium (High): Normal to Grade 2 | 81 |
| Potassium (High): Normal to Grade 3 | 18 |
| Potassium (High): Normal to Grade 4 | 8 |
| Potassium (High): Normal to Missing | 26 |
| Potassium (High): Grade 1 to Normal | 16 |
| Potassium (High): Grade 1 to 1 | 8 |
| Potassium (High): Grade 1 to 2 | 7 |
| Potassium (High): Grade 1 to 3 | 1 |
| Potassium (High): Grade 1 to Missing | 3 |
| Potassium (High): Grade 2 to Normal | 2 |
| Potassium (High): Grade 2 to 1 | 1 |
| Potassium (High): Grade 2 to 2 | 1 |
| Potassium (High): Grade 4 to Normal | 1 |
| Potassium (High): Missing to Normal | 18 |
| Potassium (High): Missing to Grade 1 | 5 |
| Potassium (High): Missing to Grade 2 | 3 |
| Potassium (High): Missing to Missing | 3 |
| Potassium (Low): Normal to Normal | 990 |
| Potassium (Low): Normal to Grade 2 | 367 |
| Potassium (Low): Normal to Missing | 29 |
| Potassium (Low): Grade 2 to Normal | 8 |
| Potassium (Low): Grade 2 to 2 | 13 |
| Potassium (Low): Missing to Normal | 19 |
| Potassium (Low): Missing to Grade 2 | 7 |
| Potassium (Low): Missing to Missing | 3 |
| Sodium (High): Normal to Normal | 1075 |
| Sodium (High): Normal to Grade 1 | 256 |
| Sodium (High): Normal to Grade 2 | 36 |
| Sodium (High): Normal to Grade 3 | 9 |
| Sodium (High): Normal to Grade 4 | 1 |
| Sodium (High): Normal to Missing | 28 |
| Sodium (High): Grade 1 to Normal | 3 |
| Sodium (High): Grade 1 to 1 | 6 |
| Sodium (High): Grade 1 to 2 | 3 |
| Sodium (High): Grade 1 to 3 | 1 |
| Sodium (High): Grade 2 to 2 | 2 |
| Sodium (High): Grade 2 to 3 | 1 |
| Sodium (High): Grade 3 to Normal | 1 |
| Sodium (High): Grade 3 to Missing | 1 |
| Sodium (High): Missing to Normal | 11 |
| Sodium (High): Missing to Grade 1 | 1 |
| Sodium (High): Missing to Missing | 1 |
| Sodium (Low): Normal to Normal | 994 |
| Sodium (Low): Normal to Grade 1 | 298 |
| Sodium (Low): Normal to Grade 3 | 20 |
| Sodium (Low): Normal to Grade 4 | 15 |
| Sodium (Low): Normal to Missing | 23 |
| Sodium (Low): Grade 1 to Normal | 21 |
| Sodium (Low): Grade 1 to 1 | 36 |
| Sodium (Low): Grade 1 to 3 | 2 |
| Sodium (Low): Grade 1 to 4 | 1 |
| Sodium (Low): Grade 1 to Missing | 6 |
| Sodium (Low): Grade 3 to Normal | 1 |
| Sodium (Low): Grade 3 to 1 | 2 |
| Sodium (Low): Grade 3 to 3 | 1 |
| Sodium (Low): Grade 4 to Normal | 2 |
| Sodium (Low): Grade 4 to 1 | 1 |
| Sodium (Low): Missing to Normal | 6 |
| Sodium (Low): Missing to Grade 1 | 5 |
| Sodium (Low): Missing to Grade 3 | 1 |
| Sodium (Low): Missing to Missing | 1 |
| Total Bilirubin: Normal to Normal | 1231 |
| Total Bilirubin: Normal to Grade 1 | 88 |
| Total Bilirubin: Normal to Grade 2 | 35 |
| Total Bilirubin: Normal to Grade 3 | 2 |
| Total Bilirubin: Normal to Missing | 28 |
| Total Bilirubin: Grade 1 to Normal | 3 |
| Total Bilirubin: Grade 1 to 1 | 11 |
| Total Bilirubin: Grade 1 to 2 | 6 |
| Total Bilirubin: Grade 1 to Missing | 2 |
| Total Bilirubin: Grade 2 to 1 | 1 |
| Total Bilirubin: Grade 2 to 2 | 1 |
| Total Bilirubin: Grade 2 to Missing | 1 |
| Total Bilirubin: Grade 3 to Normal | 1 |
| Total Bilirubin: Missing to Normal | 22 |
| Total Bilirubin: Missing to Grade 2 | 1 |
| Total Bilirubin: Missing to Missing | 3 |
| Uric Acid: Normal to Normal | 933 |
| Uric Acid: Normal to Grade 1 | 190 |
| Uric Acid: Normal to Grade 4 | 8 |
| Uric Acid: Normal to Missing | 20 |
| Uric Acid: Grade 1 to Normal | 58 |
| Uric Acid: Grade 1 to 1 | 120 |
| Uric Acid: Grade 1 to 4 | 6 |
| Uric Acid: Grade 1 to Missing | 11 |
| Uric Acid: Grade 4 to Normal | 1 |
| Uric Acid: Grade 4 to 1 | 2 |
| Uric Acid: Grade 4 to 4 | 4 |
| Uric Acid: Grade 4 to Missing | 1 |
| Uric Acid: Missing to Normal | 57 |
| Uric Acid: Missing to Grade 1 | 13 |
| Uric Acid: Missing to Grade 4 | 2 |
| Uric Acid: Missing to Missing | 10 |
Clinical laboratory tests for biochemistry parameters were performed at local laboratories. Laboratory toxicities were defined based on local laboratory normal ranges (for parameters with NCI-CTC grade not defined). Some laboratory parameters are bi-dimensional (i.e. can be graded in both the low and high direction). These parameters were split and presented in both directions. Baseline was defined as the last non-missing measurement taken prior to the first dose of study treatment (including unscheduled assessments). Values from all visits, including unscheduled visits, were included in the derivation of the worst post-baseline grade. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: was clinically significant (per investigator); was accompanied by clinical symptoms; resulted in a change in study treatment; or resulted in a medical intervention or a change in concomitant therapy.
| Participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Blood Urea Nitrogen (High): Normal to Normal | 717 |
| Blood Urea Nitrogen (High): Normal to Low | 5 |
| Blood Urea Nitrogen (High): Normal to High | 402 |
| Blood Urea Nitrogen (High): Normal to Missing | 2 |
| Blood Urea Nitrogen (High): Low to Normal | 69 |
| Blood Urea Nitrogen (High): Low to Low | 8 |
| Blood Urea Nitrogen (High): Low to High | 12 |
| Blood Urea Nitrogen (High): High to Normal | 23 |
| Blood Urea Nitrogen (High): High to High | 98 |
| Blood Urea Nitrogen (High): Missing to Normal | 42 |
| Blood Urea Nitrogen (High): Missing to High | 19 |
| Blood Urea Nitrogen (High): Missing to Missing | 39 |
| Blood Urea Nitrogen (Low): Normal to Normal | 828 |
| Blood Urea Nitrogen (Low): Normal to Low | 293 |
| Blood Urea Nitrogen (Low): Normal to High | 3 |
| Blood Urea Nitrogen (Low): Normal to Missing | 2 |
| Blood Urea Nitrogen (Low): Low to Normal | 17 |
| Blood Urea Nitrogen (Low): Low to Low | 72 |
| Blood Urea Nitrogen (Low): High to Normal | 104 |
| Blood Urea Nitrogen (Low): High to Low | 11 |
| Blood Urea Nitrogen (Low): High to High | 6 |
| Blood Urea Nitrogen (Low): Missing to Normal | 47 |
| Blood Urea Nitrogen (Low): Missing to Low | 11 |
| Blood Urea Nitrogen (Low): Missing to High | 3 |
| Blood Urea Nitrogen (Low): Missing to Missing | 39 |
| Calc Creatinine Clearance (High): Normal to Normal | 540 |
| Calc Creatinine Clearance (High): Normal to Low | 11 |
| Calc Creatinine Clearance (High): Normal to High | 201 |
| Calc Creatinine Clearance(High): Normal to Missing | 2 |
| Calc Creatinine Clearance (High): Low to Normal | 166 |
| Calc Creatinine Clearance (High): Low to Low | 107 |
| Calc Creatinine Clearance (High): Low to High | 34 |
| Calc Creatinine Clearance (High): Low to Missing | 1 |
| Calc Creatinine Clearance (High): High to Normal | 13 |
| Calc Creatinine Clearance (High): High to High | 101 |
| Calc Creatinine Clearance(High): Missing to Normal | 46 |
| Calc Creatinine Clearance (High): Missing to Low | 8 |
| Calc Creatinine Clearance (High): Missing to High | 11 |
| Calc Creatinine Clearance(High):Missing to Missing | 195 |
| Calc Creatinine Clearance (Low): Normal to Normal | 393 |
| Calc Creatinine Clearance (Low): Normal to Low | 353 |
| Calc Creatinine Clearance (Low): Normal to High | 8 |
| Calc Creatinine Clearance (Low): Low to Normal | 12 |
| Calc Creatinine Clearance (Low): Low to Low | 294 |
| Calc Creatinine Clearance (Low): Low to High | 1 |
| Calc Creatinine Clearance (Low): Low to Missing | 1 |
| Calc Creatinine Clearance (Low): High to Normal | 61 |
| Calc Creatinine Clearance (Low): High to Low | 36 |
| Calc Creatinine Clearance (Low): High to High | 17 |
| Calc Creatinine Clearance (Low): Missing to Normal | 66 |
| Calc Creatinine Clearance (Low): Missing to Low | 44 |
| Calc Creatinine Clearance (Low): Missing to High | 17 |
| Calc Creatinine Clearance(Low): Missing to Missing | 133 |
| Chloride (High): Normal to Normal | 665 |
| Chloride (High): Normal to Low | 2 |
| Chloride (High): Normal to High | 508 |
| Chloride (High): Low to Normal | 54 |
| Chloride (High): Low to High | 13 |
| Chloride (High): High to Normal | 4 |
| Chloride (High): High to High | 58 |
| Chloride (High): Missing to Normal | 41 |
| Chloride (High): Missing to High | 32 |
| Chloride (High): Missing to Missing | 59 |
| Chloride (Low): Normal to Normal | 971 |
| Chloride (Low): Normal to Low | 201 |
| Chloride (Low): Normal to High | 3 |
| Chloride (Low): Low to Normal | 31 |
| Chloride (Low): Low to Low | 36 |
| Chloride (Low): High to Normal | 57 |
| Chloride (Low): High to Low | 4 |
| Chloride (Low): High to High | 1 |
| Chloride (Low): Missing to Normal | 60 |
| Chloride (Low): Missing to Low | 13 |
| Chloride (Low): Missing to High | 1 |
| Chloride (Low): Missing to Missing | 58 |
| Lactate Dehydrogenase (High): Normal to Normal | 328 |
| Lactate Dehydrogenase (High): Normal to High | 499 |
| Lactate Dehydrogenase (High): Low to Normal | 10 |
| Lactate Dehydrogenase (High): Low to Low | 1 |
| Lactate Dehydrogenase (High): Low to High | 4 |
| Lactate Dehydrogenase (High): High to Normal | 74 |
| Lactate Dehydrogenase (High): High to High | 449 |
| Lactate Dehydrogenase (High): Missing to Normal | 16 |
| Lactate Dehydrogenase (High): Missing to High | 30 |
| Lactate Dehydrogenase (High): Missing to Missing | 25 |
| Lactate Dehydrogenase (Low): Normal to Normal | 716 |
| Lactate Dehydrogenase (Low): Normal to Low | 102 |
| Lactate Dehydrogenase (Low): Normal to High | 9 |
| Lactate Dehydrogenase (Low): Low to Normal | 5 |
| Lactate Dehydrogenase (Low): Low to Low | 9 |
| Lactate Dehydrogenase (Low): Low to High | 1 |
| Lactate Dehydrogenase (Low): High to Normal | 426 |
| Lactate Dehydrogenase (Low): High to Low | 31 |
| Lactate Dehydrogenase (Low): High to High | 66 |
| Lactate Dehydrogenase (Low): Missing to Normal | 39 |
| Lactate Dehydrogenase (Low): Missing to Low | 3 |
| Lactate Dehydrogenase (Low): Missing to High | 3 |
| Lactate Dehydrogenase (Low): Missing to Missing | 26 |
| Total Protein (High): Normal to Normal | 1091 |
| Total Protein (High): Normal to Low | 20 |
| Total Protein (High): Normal to High | 110 |
| Total Protein (High): Low to Normal | 72 |
| Total Protein (High): Low to Low | 14 |
| Total Protein (High): High to Normal | 28 |
| Total Protein (High): High to High | 24 |
| Total Protein (High): Missing to Normal | 38 |
| Total Protein (High): Missing to Low | 3 |
| Total Protein (High): Missing to High | 4 |
| Total Protein (High): Missing to Missing | 32 |
| Total Protein (Low): Normal to Normal | 530 |
| Total Protein (Low): Normal to Low | 691 |
| Total Protein (Low): Low to Normal | 4 |
| Total Protein (Low): Low to Low | 82 |
| Total Protein (Low): High to Normal | 41 |
| Total Protein (Low): High to Low | 11 |
| Total Protein (Low): Missing to Normal | 23 |
| Total Protein (Low): Missing to Low | 23 |
| Total Protein (Low): Missing to Missing | 31 |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Progression-Free Survival, as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) | 20.67 (18.89 to 23.13) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Europe | Asia | North America | South America | Africa | Other (Australia) |
|---|---|---|---|---|---|---|
| Subgroup Analysis by Region of Enrollment: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 19.38 (17.51 to 21.75) | 23.79 (15.90 to 28.85) | 25.17 (14.42 to 29.44) | 22.37 (17.51 to 32.72) | 22.83 (12.02 to 27.86) | NA (15.74 to NA) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Age ≤65 Years | Age >65 Years |
|---|---|---|
| Subgroup Analysis by Age (≤65 vs. >65 Years): Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 21.98 (19.65 to 24.25) | 14.72 (12.22 to 19.55) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | ECOG Performance Status 0 or 1 | ECOG Performance Status 2 |
|---|---|---|
| Subgroup Analysis by ECOG Performance Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 21.49 (19.45 to 23.98) | 12.88 (8.67 to 15.90) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Docetaxel | Paclitaxel | Nab-Paclitaxel |
|---|---|---|---|
| Subgroup Analysis by Taxane Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 19.38 (16.92 to 22.11) | 23.23 (19.58 to 25.59) | 19.22 (11.70 to 37.09) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Visceral Disease | Non-Visceral Disease |
|---|---|---|
| Subgroup Analysis by Visceral Disease at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 18.23 (16.13 to 20.57) | 27.24 (23.75 to 34.40) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Prior (Neo)Adjuvant Chemotherapy | No Prior (Neo)Adjuvant Chemotherapy |
|---|---|---|
| Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 19.12 (16.59 to 21.49) | 23.49 (20.57 to 25.63) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Hormone Receptor Positive | Hormone Receptor Negative | Hormone Receptor Status Unknown |
|---|---|---|---|
| Subgroup Analysis by Hormone Receptor Status at Baseline: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 20.60 (18.53 to 23.82) | 20.73 (17.05 to 23.79) | 32.13 (11.63 to 61.57) |
Progression-free survival (PFS) was defined as the time between the date of enrollment and the date of first radiographically documented progressive disease assessment (by the investigator using RECIST v1.1) or death, whichever occurred first. PFS was analyzed using a Kaplan-Meier approach. Participants who had neither progressed nor died at the time of clinical cut-off or who were lost to follow-up were censored at the date of the last evaluable tumor assessment (response assessment with the latest end date); if no post-baseline assessments were available, such participants were censored at Day 1. If a participant missed 2 or more consecutive visits, then they were censored at the last evaluable visit prior to the missed visits. Tumor assessments were performed every 3 cycles (1 cycle is 3 weeks) for up to 36 months and at least every 12 cycles thereafter during treatment, and at least every 36 weeks post-treatment (if progression-free after 36 months), until disease progression.
| Months | Previous Trastuzumab Therapy | No Previous Trastuzumab Therapy |
|---|---|---|
| Subgroup Analysis by Previous Trastuzumab Therapy: Progression-Free Survival, as Assessed by the Investigator Using RECIST v1.1 | 15.38 (13.67 to 19.02) | 23.39 (20.67 to 25.00) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Overall Survival | 65.31 (60.88 to 70.87) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Europe | Asia | North America | South America | Africa | Other (Australia) |
|---|---|---|---|---|---|---|
| Subgroup Analysis by Region of Enrollment: Overall Survival | 66.56 (61.90 to 73.49) | 63.57 (47.57 to NA) | 55.56 (41.49 to NA) | NA (49.84 to NA) | 53.22 (33.35 to 63.87) | NA (44.16 to NA) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Age ≤65 Years | Age >65 Years |
|---|---|---|
| Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Survival | 70.01 (64.33 to 81.08) | 50.10 (41.26 to 53.98) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | ECOG Performance Status 0 or 1 | ECOG Performance Status 2 |
|---|---|---|
| Subgroup Analysis by ECOG Performance Status at Baseline: Overall Survival | 67.25 (63.44 to 76.52) | 31.15 (20.50 to 39.13) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Docetaxel | Paclitaxel | Nab-Paclitaxel |
|---|---|---|---|
| Subgroup Analysis by Taxane Chemotherapy: Overall Survival | 66.53 (61.67 to 77.27) | 64.03 (56.61 to 72.25) | 70.87 (39.69 to NA) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Visceral Disease | Non-Visceral Disease |
|---|---|---|
| Subgroup Analysis by Visceral Disease at Baseline: Overall Survival | 57.10 (52.40 to 63.44) | 81.08 (71.66 to NA) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Prior (Neo)Adjuvant Chemotherapy | No Prior (Neo)Adjuvant Chemotherapy |
|---|---|---|
| Subgroup Analysis by Prior (Neo)Adjuvant Chemotherapy: Overall Survival | 57.10 (51.06 to 62.82) | 79.80 (71.79 to NA) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Hormone Receptor Positive | Hormone Receptor Negative | Hormone Receptor Status Unknown |
|---|---|---|---|
| Subgroup Analysis by Hormone Receptor Status at Baseline: Overall Survival | 66.66 (62.39 to 77.27) | 60.19 (52.34 to 67.71) | NA (16.13 to NA) |
Overall survival was defined as time from the date of enrollment until the date of death due to any cause. Overall survival was analyzed using a Kaplan-Meier approach. Participants who had not died were censored at the last date they were known to be alive. When it was not possible to confirm the full death date, partial death dates were imputed to: 01 June of that year if only the year was known, 15th of that month if only the month and year were known. If the imputed date was before the last known alive date, the last known alive date was used as the imputation.
| Months | Previous Trastuzumab Therapy | No Previous Trastuzumab Therapy |
|---|---|---|
| Subgroup Analysis by Previous Trastuzumab Therapy: Overall Survival | 54.08 (48.66 to 60.75) | 73.50 (65.61 to NA) |
The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.
| Percentage of participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1 | 79.5 (77.07 to 81.72) |
Best overall response (BOR) was defined as the best response recorded from the first dose of study treatment until disease progression/recurrence or death in the absence of disease progression. The hierarchy used to determine BOR: Complete Response (CR)\>Partial Response (PR)\>Stable Disease (SD)\>Progressive Disease (PD)\>Not Evaluable. Note that CR or PR was confirmed ≥4 weeks later. RECIST v1.1 responses are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.; PD = At least 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study, and absolute increase of ≥5 mm.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage of participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Complete Response (Confirmed) | 14.6 |
| Partial Response (Confirmed) | 64.9 |
| Stable Disease | 15.3 |
| Progressive Disease | 4.2 |
| Not Evaluable | 1.1 |
The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.
| Percentage of participants | Age ≤65 Years | Age >65 Years |
|---|---|---|
| Subgroup Analysis by Age (≤65 vs. >65 Years): Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1 | 81.7 (79.13 to 84.10) | 70.0 (63.63 to 75.85) |
The overall response rate was defined as the percentage of participants with complete response (CR) or partial response (PR) as their best confirmed response (≥4 weeks later), as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants without post-baseline tumor assessments were considered non-responders.
| Percentage of participants | Docetaxel | Paclitaxel | Nab-Paclitaxel |
|---|---|---|---|
| Subgroup Analysis by Taxane Chemotherapy: Overall Response Rate (Complete Response or Partial Response) Based on Best Overall Response (Confirmed) as Assessed by the Investigator Using RECIST v1.1 | 78.4 (75.04 to 81.48) | 82.1 (78.40 to 85.44) | 77.4 (63.79 to 87.72) |
The clinical benefit rate was defined as the percentage of participants whose best confirmed response (≥4 weeks later) was a complete response (CR) or partial response (PR), or stable disease (SD) that lasted at least 6 months, as assessed by the investigator using RECIST v1.1 from the start of study treatment until disease progression/recurrence or death. Clinical benefit responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; SD = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least 20% increase in sum of diameters of target lesions and absolute increase of ≥5 mm), taking as reference the smallest sum diameters while on study.
| Percentage of participants | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Clinical Benefit Rate (CR or PR, or SD for at Least 6 Months) Based on Best Overall Response as Assessed by the Investigator Using RECIST v.1.1 | 86.2 (84.14 to 88.13) |
Duration of response (DOR) was defined as the time from when a confirmed best overall response of complete response (CR) or partial response (PR) was first documented to first documented disease progression or death from any cause (whichever occurred first). DOR was analyzed using a Kaplan-Meier approach. Participants who had not progressed or died after having had a confirmed response were censored at the date of their last tumor measurement. Response was assessed every 3 cycles (1 cycle is 3 weeks) up to 36 months, and at least every 12 cycles thereafter until event occurrence or end of study. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Months | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Duration of Response as Assessed by the Investigator Using RECIST v1.1 | 20.01 (18.20 to 22.21) |
Time to response (TTR) was defined as the time from the first study treatment administration to the date of first confirmed response (CR or PR). TTR was analyzed using a Kaplan-Meier approach. Participants who did not have CR or PR were censored at the date of their last evaluable tumor assessment. Participants for whom no post-baseline tumor assessments were available were censored at Day 1. Responses according to RECIST v1.1 are defined as follows: CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimetres (mm).; PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Months | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Time to Response for Participants With Best Overall Response of Complete Response or Partial Response, as Assessed by the Investigator Using RECIST v1.1 | 2.464 (2.398 to 2.497) |
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. Participants were given a series of statements in each subscale and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B total score, ranging from 0 to 148, was the sum of the scores for each subscale, provided that at least 80% of the items had been answered; a higher score indicated a better quality of life. If any of the 5 subscale scores were missing, the total score was also set to missing. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
| Score on a scale | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Baseline (BL): Absolute Value at Visit | 99.87 ± 20.548 |
| Change from BL at Cycle 3 | 0.40 ± 15.526 |
| Change from BL at Cycle 6 | -1.93 ± 17.611 |
| Change from BL at Cycle 9 | 0.87 ± 17.211 |
| Change from BL at Cycle 12 | 3.03 ± 17.426 |
| Change from BL at Cycle 15 | 3.33 ± 18.764 |
| Change from BL at Cycle 18 | 3.80 ± 18.689 |
| Change from BL at Cycle 21 | 4.06 ± 18.175 |
| Change from BL at Cycle 24 | 3.59 ± 19.570 |
| Change from BL at Cycle 27 | 3.14 ± 20.311 |
| Change from BL at Cycle 30 | 3.75 ± 18.877 |
| Change from BL at Cycle 33 | 3.58 ± 20.586 |
| Change from BL at Cycle 36 | 3.16 ± 18.838 |
| Change from BL at Cycle 39 | 1.66 ± 19.791 |
| Change from BL at Cycle 42 | 2.08 ± 20.658 |
| Change from BL at Cycle 45 | 2.22 ± 20.811 |
| Change from BL at Cycle 48 | 1.51 ± 21.268 |
| Change from BL at Cycle 51 | 1.95 ± 20.221 |
| Change from BL at Cycle 54 | 0.52 ± 20.784 |
| Change from BL at Cycle 57 | 0.54 ± 20.014 |
| Change from BL at Cycle 60 | 0.20 ± 21.207 |
| Change from BL at Cycle 63 | 0.61 ± 21.475 |
| Change from BL at Cycle 66 | 0.44 ± 20.633 |
| Change from BL at Cycle 69 | -0.75 ± 21.419 |
| Change from BL at Cycle 72 | -1.16 ± 21.951 |
| Change from BL at Cycle 75 | -1.14 ± 21.132 |
| Change from BL at Cycle 78 | 0.11 ± 20.807 |
| Change from BL at Cycle 81 | -1.03 ± 20.526 |
| Change from BL at Cycle 84 | -1.67 ± 21.030 |
| Change from BL at Cycle 87 | 0.62 ± 21.183 |
| Change from BL at Cycle 90 | 0.00 ± 22.289 |
| Change from BL at Cycle 93 | 0.99 ± 21.474 |
| Change from BL at Cycle 96 | 2.36 ± 21.636 |
| Change from BL at Cycle 99 | 1.36 ± 23.195 |
| Change from BL at Cycle 102 | 1.20 ± 21.262 |
| Change from BL at Cycle 105 | 3.13 ± 20.385 |
| Change from BL at Cycle 108 | 2.22 ± 23.617 |
| Change from BL at Cycle 111 | -0.48 ± 22.585 |
| Change from BL at Cycle 114 | -4.42 ± 22.323 |
| Change from BL at Cycle 117 | -4.96 ± 16.232 |
| Change from BL at Cycle 120 | -8.64 ± 13.187 |
| Change from BL at Cycle 123 | -20.94 ± 2.357 |
| Change from BL at End of Treatment | -1.06 ± 19.923 |
| Change from BL at Day 28 of Follow-Up | -1.96 ± 21.201 |
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the physical well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B physical well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
| Score on a scale | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Baseline (BL): Absolute Value at Visit | 20.98 ± 6.044 |
| Change from BL at Cycle 3 | -1.13 ± 5.557 |
| Change from BL at Cycle 6 | -1.61 ± 5.994 |
| Change from BL at Cycle 9 | -0.31 ± 5.604 |
| Change from BL at Cycle 12 | 0.51 ± 5.599 |
| Change from BL at Cycle 15 | 0.51 ± 5.652 |
| Change from BL at Cycle 18 | 0.69 ± 5.543 |
| Change from BL at Cycle 21 | 0.73 ± 5.616 |
| Change from BL at Cycle 24 | 0.61 ± 5.690 |
| Change from BL at Cycle 27 | 0.47 ± 5.761 |
| Change from BL at Cycle 30 | 0.71 ± 5.584 |
| Change from BL at Cycle 33 | 0.56 ± 5.894 |
| Change from BL at Cycle 36 | 0.39 ± 5.512 |
| Change from BL at Cycle 39 | -0.04 ± 5.647 |
| Change from BL at Cycle 42 | 0.22 ± 5.604 |
| Change from BL at Cycle 45 | 0.09 ± 5.698 |
| Change from BL at Cycle 48 | 0.11 ± 5.564 |
| Change from BL at Cycle 51 | 0.22 ± 5.280 |
| Change from BL at Cycle 54 | -0.26 ± 5.765 |
| Change from BL at Cycle 57 | -0.35 ± 5.695 |
| Change from BL at Cycle 60 | -0.10 ± 5.630 |
| Change from BL at Cycle 63 | -0.20 ± 5.696 |
| Change from BL at Cycle 66 | 0.29 ± 5.338 |
| Change from BL at Cycle 69 | -0.60 ± 5.579 |
| Change from BL at Cycle 72 | -0.35 ± 5.494 |
| Change from BL at Cycle 75 | -0.72 ± 5.507 |
| Change from BL at Cycle 78 | -0.44 ± 5.379 |
| Change from BL at Cycle 81 | -0.65 ± 5.029 |
| Change from BL at Cycle 84 | -0.81 ± 5.249 |
| Change from BL at Cycle 87 | -0.36 ± 5.391 |
| Change from BL at Cycle 90 | -0.66 ± 5.332 |
| Change from BL at Cycle 93 | -0.42 ± 5.788 |
| Change from BL at Cycle 96 | -0.28 ± 5.178 |
| Change from BL at Cycle 99 | -0.21 ± 5.474 |
| Change from BL at Cycle 102 | -0.80 ± 5.269 |
| Change from BL at Cycle 105 | -0.07 ± 5.133 |
| Change from BL at Cycle 108 | 0.07 ± 5.775 |
| Change from BL at Cycle 111 | 0.38 ± 5.309 |
| Change from BL at Cycle 114 | -1.70 ± 4.950 |
| Change from BL at Cycle 117 | -1.83 ± 3.474 |
| Change from BL at Cycle 120 | -2.38 ± 3.092 |
| Change from BL at Cycle 123 | -5.58 ± 2.946 |
| Change from BL at End of Treatment | -0.73 ± 6.366 |
| Change from BL at Day 28 of Follow-Up | -0.95 ± 6.393 |
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the social well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B social well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
| Score on a scale | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Baseline (BL): Absolute Value at Visit | 22.24 ± 4.993 |
| Change from BL at Cycle 3 | -0.41 ± 4.145 |
| Change from BL at Cycle 6 | -1.09 ± 4.320 |
| Change from BL at Cycle 9 | -1.02 ± 4.728 |
| Change from BL at Cycle 12 | -1.19 ± 4.846 |
| Change from BL at Cycle 15 | -1.28 ± 4.949 |
| Change from BL at Cycle 18 | -1.19 ± 4.986 |
| Change from BL at Cycle 21 | -1.24 ± 4.881 |
| Change from BL at Cycle 24 | -1.26 ± 4.856 |
| Change from BL at Cycle 27 | -1.48 ± 4.994 |
| Change from BL at Cycle 30 | -1.18 ± 5.107 |
| Change from BL at Cycle 33 | -1.45 ± 4.852 |
| Change from BL at Cycle 36 | -1.54 ± 4.953 |
| Change from BL at Cycle 39 | -1.77 ± 5.066 |
| Change from BL at Cycle 42 | -1.73 ± 5.154 |
| Change from BL at Cycle 45 | -1.50 ± 5.238 |
| Change from BL at Cycle 48 | -1.84 ± 5.475 |
| Change from BL at Cycle 51 | -2.01 ± 5.657 |
| Change from BL at Cycle 54 | -1.77 ± 5.236 |
| Change from BL at Cycle 57 | -1.88 ± 5.117 |
| Change from BL at Cycle 60 | -2.01 ± 5.528 |
| Change from BL at Cycle 63 | -2.18 ± 5.278 |
| Change from BL at Cycle 66 | -2.19 ± 5.586 |
| Change from BL at Cycle 69 | -2.24 ± 5.434 |
| Change from BL at Cycle 72 | -2.49 ± 5.846 |
| Change from BL at Cycle 75 | -2.40 ± 5.777 |
| Change from BL at Cycle 78 | -2.33 ± 5.676 |
| Change from BL at Cycle 81 | -2.53 ± 5.609 |
| Change from BL at Cycle 84 | -2.96 ± 5.624 |
| Change from BL at Cycle 87 | -2.29 ± 5.487 |
| Change from BL at Cycle 90 | -2.38 ± 5.355 |
| Change from BL at Cycle 93 | -1.97 ± 5.102 |
| Change from BL at Cycle 96 | -1.94 ± 4.831 |
| Change from BL at Cycle 99 | -2.07 ± 5.316 |
| Change from BL at Cycle 102 | -1.70 ± 4.258 |
| Change from BL at Cycle 105 | -1.76 ± 4.074 |
| Change from BL at Cycle 108 | -1.75 ± 3.387 |
| Change from BL at Cycle 111 | -1.94 ± 3.663 |
| Change from BL at Cycle 114 | -2.31 ± 3.386 |
| Change from BL at Cycle 117 | -1.83 ± 3.600 |
| Change from BL at Cycle 120 | -2.85 ± 5.485 |
| Change from BL at Cycle 123 | -1.92 ± 2.946 |
| Change from BL at End of Treatment | -1.29 ± 4.911 |
| Change from BL at Day 28 of Follow-Up | -1.61 ± 5.080 |
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the emotional well-being subscale, participants were given a series of 6 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B emotional well-being subscale score, ranging from 0 to 24, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
| Score on a scale | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Baseline (BL): Absolute Value at Visit | 15.08 ± 4.990 |
| Change from BL at Cycle 3 | 1.69 ± 4.219 |
| Change from BL at Cycle 6 | 1.53 ± 4.526 |
| Change from BL at Cycle 9 | 1.64 ± 4.624 |
| Change from BL at Cycle 12 | 2.02 ± 4.686 |
| Change from BL at Cycle 15 | 1.98 ± 4.778 |
| Change from BL at Cycle 18 | 2.03 ± 4.861 |
| Change from BL at Cycle 21 | 2.17 ± 4.877 |
| Change from BL at Cycle 24 | 2.19 ± 5.040 |
| Change from BL at Cycle 27 | 2.21 ± 5.171 |
| Change from BL at Cycle 30 | 2.17 ± 4.763 |
| Change from BL at Cycle 33 | 2.21 ± 5.275 |
| Change from BL at Cycle 36 | 2.32 ± 5.130 |
| Change from BL at Cycle 39 | 1.99 ± 5.115 |
| Change from BL at Cycle 42 | 1.96 ± 5.451 |
| Change from BL at Cycle 45 | 2.25 ± 5.367 |
| Change from BL at Cycle 48 | 1.82 ± 5.414 |
| Change from BL at Cycle 51 | 2.32 ± 5.311 |
| Change from BL at Cycle 54 | 1.84 ± 5.325 |
| Change from BL at Cycle 57 | 1.80 ± 5.256 |
| Change from BL at Cycle 60 | 1.59 ± 5.462 |
| Change from BL at Cycle 63 | 1.70 ± 5.336 |
| Change from BL at Cycle 66 | 1.52 ± 5.074 |
| Change from BL at Cycle 69 | 1.83 ± 5.351 |
| Change from BL at Cycle 72 | 1.56 ± 5.421 |
| Change from BL at Cycle 75 | 1.58 ± 5.308 |
| Change from BL at Cycle 78 | 1.72 ± 5.463 |
| Change from BL at Cycle 81 | 2.01 ± 5.750 |
| Change from BL at Cycle 84 | 2.06 ± 5.384 |
| Change from BL at Cycle 87 | 1.97 ± 5.558 |
| Change from BL at Cycle 90 | 2.08 ± 5.686 |
| Change from BL at Cycle 93 | 2.17 ± 5.388 |
| Change from BL at Cycle 96 | 2.40 ± 5.769 |
| Change from BL at Cycle 99 | 2.30 ± 6.041 |
| Change from BL at Cycle 102 | 2.07 ± 5.949 |
| Change from BL at Cycle 105 | 2.58 ± 5.902 |
| Change from BL at Cycle 108 | 2.34 ± 6.721 |
| Change from BL at Cycle 111 | 1.19 ± 7.241 |
| Change from BL at Cycle 114 | 1.55 ± 7.944 |
| Change from BL at Cycle 117 | 1.33 ± 4.185 |
| Change from BL at Cycle 120 | 0.75 ± 2.217 |
| Change from BL at Cycle 123 | -0.50 ± 2.121 |
| Change from BL at End of Treatment | 0.30 ± 5.001 |
| Change from BL at Day 28 of Follow-Up | 0.37 ± 5.193 |
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the functional well-being subscale, participants were given a series of 7 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B functional well-being subscale score, ranging from 0 to 28, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
| Score on a scale | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Baseline (BL): Absolute Value at Visit | 16.65 ± 6.096 |
| Change from BL at Cycle 3 | -0.47 ± 4.961 |
| Change from BL at Cycle 6 | -0.79 ± 5.437 |
| Change from BL at Cycle 9 | -0.11 ± 5.572 |
| Change from BL at Cycle 12 | 0.46 ± 5.577 |
| Change from BL at Cycle 15 | 0.78 ± 5.758 |
| Change from BL at Cycle 18 | 0.83 ± 5.797 |
| Change from BL at Cycle 21 | 0.89 ± 5.804 |
| Change from BL at Cycle 24 | 0.53 ± 5.903 |
| Change from BL at Cycle 27 | 0.71 ± 6.064 |
| Change from BL at Cycle 30 | 0.60 ± 5.961 |
| Change from BL at Cycle 33 | 0.67 ± 6.209 |
| Change from BL at Cycle 36 | 0.52 ± 5.687 |
| Change from BL at Cycle 39 | 0.26 ± 5.927 |
| Change from BL at Cycle 42 | 0.31 ± 6.038 |
| Change from BL at Cycle 45 | 0.34 ± 6.049 |
| Change from BL at Cycle 48 | 0.28 ± 6.227 |
| Change from BL at Cycle 51 | 0.23 ± 5.931 |
| Change from BL at Cycle 54 | -0.06 ± 6.090 |
| Change from BL at Cycle 57 | 0.21 ± 5.925 |
| Change from BL at Cycle 60 | 0.01 ± 6.100 |
| Change from BL at Cycle 63 | -0.06 ± 6.178 |
| Change from BL at Cycle 66 | -0.07 ± 6.264 |
| Change from BL at Cycle 69 | -0.47 ± 6.476 |
| Change from BL at Cycle 72 | -0.50 ± 6.378 |
| Change from BL at Cycle 75 | -0.40 ± 6.391 |
| Change from BL at Cycle 78 | -0.18 ± 6.197 |
| Change from BL at Cycle 81 | -0.29 ± 6.046 |
| Change from BL at Cycle 84 | -0.48 ± 6.022 |
| Change from BL at Cycle 87 | -0.08 ± 6.250 |
| Change from BL at Cycle 90 | 0.16 ± 6.587 |
| Change from BL at Cycle 93 | 0.58 ± 6.161 |
| Change from BL at Cycle 96 | 1.27 ± 6.663 |
| Change from BL at Cycle 99 | 0.46 ± 6.651 |
| Change from BL at Cycle 102 | 0.96 ± 6.327 |
| Change from BL at Cycle 105 | 1.14 ± 5.922 |
| Change from BL at Cycle 108 | 1.42 ± 6.902 |
| Change from BL at Cycle 111 | 0.32 ± 6.507 |
| Change from BL at Cycle 114 | -0.25 ± 6.439 |
| Change from BL at Cycle 117 | -0.58 ± 5.316 |
| Change from BL at Cycle 120 | -2.00 ± 3.916 |
| Change from BL at Cycle 123 | -5.00 ± 2.828 |
| Change from BL at End of Treatment | -0.50 ± 6.132 |
| Change from BL at Day 28 of Follow-Up | -0.70 ± 6.558 |
The FACT-B questionnaire (version 4) was administered only to female participants to assess quality of life in five subscales: physical, social, emotional, and functional well-being, and breast cancer. For the breast cancer subscale, participants were given a series of 10 statements and were asked to rate how true each statement was for them during the past 7 days on a 5-point scale ranging from 0 (not at all) to 4 (very much). The calculated FACT-B breast cancer subscale score, ranging from 0 to 40, was the sum of the scores for each statement only if at least 50% of items had been answered; the higher the score, the better the quality of life. Baseline was defined as the last non-missing measurement taken prior to first dose of study treatment (including unscheduled assessments). Post-baseline values were summarized for planned visits only.
| Score on a scale | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Baseline (BL): Absolute Value at Visit | 24.98 ± 6.296 |
| Change from BL at Cycle 3 | 0.48 ± 5.101 |
| Change from BL at Cycle 6 | -0.11 ± 5.759 |
| Change from BL at Cycle 9 | 0.52 ± 5.633 |
| Change from BL at Cycle 12 | 0.89 ± 5.770 |
| Change from BL at Cycle 15 | 1.16 ± 6.180 |
| Change from BL at Cycle 18 | 1.30 ± 6.043 |
| Change from BL at Cycle 21 | 1.30 ± 5.898 |
| Change from BL at Cycle 24 | 1.39 ± 6.231 |
| Change from BL at Cycle 27 | 1.17 ± 6.043 |
| Change from BL at Cycle 30 | 1.34 ± 5.968 |
| Change from BL at Cycle 33 | 1.34 ± 6.113 |
| Change from BL at Cycle 36 | 1.33 ± 6.030 |
| Change from BL at Cycle 39 | 1.12 ± 6.210 |
| Change from BL at Cycle 42 | 1.11 ± 6.499 |
| Change from BL at Cycle 45 | 1.13 ± 6.414 |
| Change from BL at Cycle 48 | 1.00 ± 6.679 |
| Change from BL at Cycle 51 | 0.99 ± 6.430 |
| Change from BL at Cycle 54 | 0.76 ± 6.555 |
| Change from BL at Cycle 57 | 0.70 ± 6.355 |
| Change from BL at Cycle 60 | 0.80 ± 6.586 |
| Change from BL at Cycle 63 | 1.32 ± 6.960 |
| Change from BL at Cycle 66 | 0.74 ± 6.822 |
| Change from BL at Cycle 69 | 0.54 ± 6.532 |
| Change from BL at Cycle 72 | 0.50 ± 7.142 |
| Change from BL at Cycle 75 | 0.85 ± 6.925 |
| Change from BL at Cycle 78 | 1.22 ± 6.899 |
| Change from BL at Cycle 81 | 0.27 ± 7.100 |
| Change from BL at Cycle 84 | 0.55 ± 6.690 |
| Change from BL at Cycle 87 | 1.17 ± 6.882 |
| Change from BL at Cycle 90 | 0.51 ± 7.313 |
| Change from BL at Cycle 93 | 0.30 ± 7.163 |
| Change from BL at Cycle 96 | 0.65 ± 6.240 |
| Change from BL at Cycle 99 | 1.19 ± 6.957 |
| Change from BL at Cycle 102 | 0.56 ± 6.189 |
| Change from BL at Cycle 105 | 0.68 ± 6.399 |
| Change from BL at Cycle 108 | 0.19 ± 6.982 |
| Change from BL at Cycle 111 | 0.01 ± 6.814 |
| Change from BL at Cycle 114 | -1.67 ± 5.963 |
| Change from BL at Cycle 117 | -1.56 ± 5.842 |
| Change from BL at Cycle 120 | -2.17 ± 6.055 |
| Change from BL at Cycle 123 | -7.94 ± 7.307 |
| Change from BL at End of Treatment | 0.88 ± 6.574 |
| Change from BL at Day 28 of Follow-Up | 0.66 ± 6.477 |
Collected over From Baseline until 28 days after last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab + Trastuzumab + Taxane | 658/1,436 (45.8%) | 535/1,436 (37.3%) | 1,394/1,436 (97.1%) |
| Event | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 71/1436 |
| NeutropeniaBlood and lymphatic system disorders | 47/1436 |
| DiarrhoeaGastrointestinal disorders | 36/1436 |
| PneumoniaInfections and infestations | 26/1436 |
| Drug hypersensitivityImmune system disorders | 20/1436 |
| PyrexiaGeneral disorders | 18/1436 |
| Ejection fraction decreasedInvestigations | 18/1436 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 16/1436 |
| CellulitisInfections and infestations | 15/1436 |
| Urinary tract infectionInfections and infestations | 15/1436 |
| Event | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| DiarrhoeaGastrointestinal disorders | 974/1436 |
| AlopeciaSkin and subcutaneous tissue disorders | 693/1436 |
| NauseaGastrointestinal disorders | 512/1436 |
| FatigueGeneral disorders | 457/1436 |
| AstheniaGeneral disorders | 426/1436 |
| RashSkin and subcutaneous tissue disorders | 365/1436 |
| VomitingGastrointestinal disorders | 340/1436 |
| HeadacheNervous system disorders | 328/1436 |
| Neuropathy peripheralNervous system disorders | 328/1436 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 328/1436 |
| Age, Continuous(Years) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Mean | 54.4 ± 12.10 |
| Sex: Female, Male(Participants) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Female | 1429 |
| Male | 7 |
| Race/Ethnicity, Customized(Participants) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Caucasian | 1032 |
| Black | 9 |
| Asian | 88 |
| Native American | 28 |
| Other | 57 |
| Not Applicable as per Local Regulations | 222 |
| Age Categorical (≤65 or >65 Years Old)(Participants) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| ≤65 Years Old | 1167 |
| >65 Years Old | 269 |
| Ethnicity(Participants) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Hispanic/Latino | 269 |
| Chinese | 57 |
| Japanese | 2 |
| Mixed Ethnicity | 18 |
| Indian | 21 |
| Other | 495 |
| Not Applicable as per Local Regulations | 574 |
| Geographic Region of Enrollment(Participants) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Europe | 1009 |
| Asia | 177 |
| North America | 34 |
| South America | 121 |
| Africa | 71 |
| Other (Australia) | 24 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline(Participants) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Grade 0 or 1 | 1371 |
| Grade 2 | 63 |
| Missing | 2 |
| Visceral Disease at Baseline(Participants) | Pertuzumab + Trastuzumab + Taxane |
|---|---|
| Visceral Disease | 992 |
| Non-visceral Disease | 444 |
5 further baseline measures are reported on the registry.
Showing the first 100 of 299 sites across 39 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2012 to primary completion in Sep 2019, 87 months.
Results were first posted in Sep 2020, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 87 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab